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Reproductive Genetic Testing: Issues and Options for Policymakers
We are currently in the midst of a genetic revolution in medicine. Advances in 
science, especially the completion of the human genome sequence, have led to greater 
understanding of the role of genes in health and disease. Genetic tests for diseases and 
disease risks are available currently and new medicines and preventive strategies are on 
the horizon. 
Many people fi rst encounter genetic testing when having a baby. Reproductive genetic 
testing – carrier testing, prenatal genetic testing, preimplantation genetic diagnosis 
– combines the newest advances in genetics with the most profound human activity of 
creating life.  Reproductive genetic testing provides information: information about the 
risk of parents passing a genetic mutation to their children; information about the genetic 
characteristics of embryos produced through in vitro fertilization; information about 
the genome of a fetus in utero.  Th is information can provide reassurance to prospective 
parents, or be the basis for important decisions: to attempt a pregnancy or not; to transfer 
an embryo to the uterus or not; to continue a pregnancy or not.  Th e growing availability 
and use of reproductive genetic testing presents a host of complicated ethical, legal and 
social issues.  
New genetic technologies will touch the lives of millions of Americans. Yet, there 
is relatively little oversight of reproductive genetic testing.  As the number and type 
of genetic tests grows and their use becomes more widespread, the time has come to 
seriously consider how these new technologies will aff ect individuals and shape society, 
and whether changes in oversight are needed.  Some believe that the decision to use 
reproductive genetic testing should be left  up to individual parents in consultation with 
their doctors. Others believe that reproductive genetic tests for certain uses are ethically 
inappropriate and that the tests should be either controlled stringently or banned 
entirely. Th e challenge is to consider the scientifi c, ethical, social and political issues these 
technologies raise in formulating policies that also refl ect the public’s values and enhance 
the public good.  
Th is report, Reproductive Genetic Testing: Issues and Options for Policymakers, aims to 
help focus and facilitate the discussion about reproductive genetic testing by outlining 
key scientifi c and medical facts, considering ethical and social implications, and assessing 
both current and potential oversight for the development and use of reproductive genetic 
tests. It presents a range of policy options supported by expert analysis that consider the 
potential eff ects, positive and negative, of distinctly diff erent policy directions. Our goal at 
the Genetics and Public Policy Center is not to advocate for or against any technology or 
policy outcome but to make sure that policy decisions, including the decision to maintain 
the status quo, are undertaken with a clear-eyed understanding of their potential impact. 
Th e growing debate about the use and oversight of reproductive genetic testing has 
been largely framed by two opposing views: those who see reproductive genetic testing as 
an opportunity to prevent suff ering and who oppose limitations on research, technological 
advance and reproductive choice; and those who believe that reproductive genetic 
testing will have adverse ethical and social impacts and who support restrictions on its 
development and use. Th e views of most Americans, however, are more nuanced and 
elastic, refl ecting the tensions among hopes, values and personal experience.
1
Preface
2 Reproductive Genetic Testing: Issues and Options for Policymakers 
Th e Center has undertaken an in-depth eff ort to assess public attitudes toward genetic 
technologies – with public opinion surveys, town halls, focus groups, and online group 
discussions – as a means of making the discussion about genetics and public policy 
more democratic and less divisive and the province of special interests. Th e goal is not to 
encourage policy making by public referendum, but to give everyone involved a clearer 
sense of the diversity of opinion surrounding these issues.
In 2004, we organized public meetings around the country and invited those whose 
voices are not typically heard by policy makers; we held meetings with stakeholders 
to gather their input on policy options; we held interactive forums online that allowed 
individuals to register their opinions; we conducted the largest ever survey of the 
American public about their opinions of reproductive genetic testing and technologies. 
Th e accompanying report, Reproductive Genetic Testing: What America Th inks, presents 
the results of our research on the public’s attitudes about reproductive genetic testing and 
possible approaches to its oversight.
We hope that together these two reports will be useful tools for enhancing public 
discussion of reproductive technologies and assisting decision makers in both the 
private and public sectors as they consider policies to govern the development and use of 
reproductive genetic testing.
Kathy Hudson
Director, Genetics & Public Policy Center
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Genetic testing is undergoing 
tremendous changes.  Scientists 
are identifying disease-causing 
mutations in human genes at a rapid 
pace and developing tests to detect 
them.  In addition, new laboratory 
technologies will allow many genetic 
tests to be performed at once on 
a single sample of DNA.  Th ese 
developments are part of an ongoing 
“genetic revolution” in medicine 
and biotechnology.  Tests to detect 
the presence of a genetic mutation 
or abnormal chromosomes can 
help diagnose an existing disease 
or can be used to predict either the 
certainty or probability that a disease 
will develop in the future.
 
Many people fi rst encounter 
genetic testing in the reproductive 
context as genetic testing has 
become an integral component 
of reproductive health care. 
Reproductive genetic testing refers 
to those genetic tests and procedures 
that are used to provide prospective 
parents with information about 
their chances of having a child 
with a specifi c genetic disorder 
or characteristic in a current or 
future pregnancy.  Th ese include: 
(1) carrier testing, which is done to 
determine whether an individual 
carries one copy of an altered gene 
for a particular recessive condition; 
(2) prenatal genetic testing, in 
which the cells of a developing fetus 
obtained through procedures such 
as amniocentesis and chorionic 
villus sampling (CVS) are genetically 
tested; and (3) preimplantation 
genetic diagnosis (PGD), in which 
embryos produced through in vitro 
fertilization (IVF) are genetically 
tested to select which embryos to 
transfer to a woman’s uterus. 
For many, reproductive genetic 
tests ultimately provide extremely 
valuable and reassuring information.  
But the experience of reproductive 
genetic testing is oft en not easy.  
Women sometimes report feeling 
they have boarded a roller coaster 
ride of choices that may include 
discovering their child has an 
increased risk of genetic disease, 
undertaking invasive genetic testing 
procedures, making decisions 
regarding termination or bearing 
a child with a potentially serious 
condition and assessing whether and 
how to approach future pregnancies.  
Th ere are many alternative 
policies—some complementary, 
some confl icting — that could 
guide the development and use 
of reproductive genetic testing. 
Currently, prospective parents 
decide whether to seek reproductive 
genetic testing to detect a particular 
condition or trait. Providers and 
clinical laboratories, in turn, make 
the decisions about what genetic 
tests they will off er. Some individual 
clinics and providers may refuse to 
perform testing for certain reasons, 
such as sex selection. A “status quo” 
policy approach would leave the 
current system in place, avoiding 
government interference in personal 
reproductive choices and the practice 
of medicine.  It would also allow 
scientifi c and medical advances 
to move forward unimpeded 
by government restraints. Some 
observers are content with this level 
of oversight.
Others believe that decisions 
about technologies so profound that 
they could shape future generations 
should not be left  entirely to the 
discretion of individual parents and 
providers. Th ey raise concerns about 
the inappropriate use of reproductive 
genetic tests and believe that broader 
societal consensus and input are 
needed.  Some believe scientifi c and 
technologic capability itself will drive 
practice to move forward, regardless 
of what society may believe is 
ethical.  Others question how safe, 
accurate, eff ective and benefi cial 
these technologies are, and whether 
as a society we have allowed them 
to become commonplace without 
fully considering their implications.  
Some worry that any benefi ts from 
these technologies will be inequitably 
distributed because of their high 
cost.
Many observers believe new 
policies — governmental or private 
— are needed to keep pace with 
the rapid changes in reproductive 
genetic testing.  Oversight can 
spur good development and uses 
of new or existing tests and avoid 
inappropriate uses or outcomes.  
Some people want to limit or ban 
reproductive genetic testing. An 
outright ban of all testing is unlikely, 
as some forms of genetic testing 
have already become a routine part 
of reproductive health care, one that 
prospective parents know about 
and expect to be off ered whether 
or not they choose to pursue these 
tests.  Even so, some countries, 
Reproductive genetic testing refers 
to those tests and procedures that 
are used to provide prospective 
parents with information about 
their chances of having a child 
with a specifi c genetic disorder or 
characteristic in a current or future 
pregnancy. 
Introduction
4 Reproductive Genetic Testing: Issues and Options for Policymakers 
including the United Kingdom, 
France, Germany and India have 
enacted laws setting limits on the 
use of prenatal genetic testing.  
Th e emergence of PGD has been 
suffi  ciently troubling to some that 
its use has been prohibited in some 
countries such as Germany and 
Switzerland.
Ultimately, policymakers face 
the challenge of balancing personal 
values of liberty and choice  with 
more community-based values such 
as ensuring that society is the kind of 
place that individuals want to live.
Th is report, Reproductive 
Genetic Testing: Issues and Options 
for Policymakers, addresses the 
scientifi c, legal, regulatory, ethical, 
moral and societal issues raised by 
carrier testing, prenatal screening 
and testing and PGD. It also lays out 
an array of possible policy options 
to guide the development and use of 
reproductive genetic testing.  
Th e options presented here 
seek to explore the full measure of 
possible policy approaches, including 
federal, state and non-governmental 
strategies to address the issues 
surrounding reproductive genetic 
testing. Each option includes a brief 
overview of its purpose and potential 
implications, and explains some of 
the arguments that could be made in 
support or opposition. 
Ultimately, one’s policy 
preferences are likely to be 
infl uenced by a range of factors, 
including perceptions of existing 
and likely future applications of 
reproductive genetic testing and 
one’s view of the proper balance 
between governmental involvement 
and individual liberty. Th ese 
preferences also frequently turn 
on core beliefs about the moral 
and ethical acceptability of genetic 
testing, abortion and destruction of 
human embryos. One’s perspective 
may also include assumptions about 
the expected costs and benefi ts 
of various applications of these 
technologies and how they will be 
distributed in society. 
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Reproductive Genetic Testing:  
A Scientifi c and Medical Overview
Genes and Inheritance
Advances in reproductive 
genetic testing have emerged from 
our growing knowledge of how 
an individual’s genetic blueprint is 
linked to inherited characteristics 
such as risk of disease. To 
understand what is behind this 
technology, it is worth reviewing 
some fundamental facts of human 
biology and genetics.
Every person is born with a 
genetic code that is made up of 
DNA. DNA is composed of four 
chemical subunits, or nucleotides, 
abbreviated as A, T, C and G. Th ese 
subunits come together as pairs; 
an A always pairs with a T and a C 
always pairs with a G, to form the 
rungs of a twisting ladder called the 
DNA double helix.  
Th e sequence of these base pairs 
along the double helix represents a 
code or set of instructions.  A length 
of DNA encoding an instruction, 
such as for the manufacture of a 
certain protein, is called a gene. It is 
estimated that humans have 20,000 
to 25,000 genes. 
Th e DNA in each human 
cell is packaged into 23 pairs of 
chromosomes within the cell’s 
nucleus. Our chromosomes and the 
genes they carry are inherited from 
our parents. During fertilization, 
half of the nuclear DNA, or 23 
chromosomes, comes from the 
mother’s egg. Th e other half comes 
from the father’s sperm. Th ese 
chromosomes contain all the genetic 
instructions necessary to create 
new life. As an embryo develops 
and cells divide, the complete DNA 
blueprint is copied over and over 
into each new cell.  A small amount 
of DNA also is contained in cellular 
structures called the mitochondria, 
which are inherited only from the 
mother. 
Genes and their Role in Disease
We all carry alterations, or 
variations, in our genetic code. Th e 
DNA from any two people is 99.9 
percent identical. But one-tenth of 
one percent is diff erent between any 
two individuals and this diff erence is 
part of what makes a person unique.  
Many of these variations in the 
DNA code have no harmful eff ect.  
Other variations can cause disease 
or increase the risk of disease. 
Sometimes, a change in only one or 
a few letters in a gene can cause a 
gene to malfunction, e.g. produce a 
non-functioning protein or fail to 
produce a protein at all.  Variations 
with deleterious consequences are 
generally referred to as genetic 
“mutations.”  An inherited disease 
or condition, such as Huntington 
disease, cystic fi brosis or sickle cell 
anemia, can be caused by one or 
more mutations in a single gene. 
We all have two copies of 
each gene on our “autosomal” 
chromosomes, meaning those other 
than the X and Y chromosomes 
DNA double helix shows pairing of A to T and C to G. The order of the base 
pairs in a gene provides the instructions to make a protein. A variation occurs 
in one gene. The gene on one chromosome contains a T-A and the other a G-C.
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that determine sex. Sometimes 
both copies of a gene must have 
a mutation to cause disease. Such 
mutations are called “recessive.”  A 
person who carries only one copy of 
a recessive gene mutation is called a 
“carrier.”  Carriers are usually healthy 
but if two carriers have a child, then 
there is a 25 percent chance that 
their child will receive two copies of 
the mutation, one from each parent, 
and be aff ected by the disease.
Some genes are on the X or Y 
chromosome.  Such genes are termed 
“X- or Y- linked.” Th e impact of an 
X-linked recessive mutation will 
be diff erent in males, who have 
one X and one Y chromosome, 
and females, who have two X 
chromosomes.  For example, the 
recessive mutation that causes 
Duchenne muscular dystrophy is on 
the X chromosome. A female who 
has one copy of the mutation will 
be a carrier, since she will have a 
normal copy of the gene on her other 
X chromosome.  A male who has 
the mutation on his X chromosome, 
however, will have the disease, since 
he has only one X chromosome. 
Th us, each male child of a mother 
who is a carrier has a 50 percent 
risk of inheriting the mutation and 
developing Duchenne muscular 
dystrophy.  Each female child has a 
50 percent chance of being a carrier 
like her mother. 
Sometimes, a mutation in 
only one copy of a gene can cause 
disease.  Such mutations are called 
“dominant.”  If one member of a 
couple has a dominant mutation 
then there is a 50 percent chance that 
each child will inherit the dominant 
mutation and also be aff ected.   
Sometimes genetic diseases 
are the result of chromosomal 
abnormalities.  A person may 
have too many or too few copies 
of a particular chromosome, or 
have a missing or extra region of a 
chromosome. For example, Down 
syndrome is caused by the presence 
of an extra copy of chromosome 21.  
Many chromosomal abnormalities 
are incompatible with life and 
result in pregnancy loss or stillbirth 
whereas others can cause birth 
defects, developmental delays or 
mental retardation.
The Limits of Genetics
Many health conditions are not 
caused by mutations in a single 
gene but rather involve multiple 
genes and their interaction with 
the environment.  A major focus of 
modern biomedical research is to 
identify those genes that contribute 
to common disorders such as 
heart disease, diabetes, asthma and 
most cancers.  Th ese conditions 
are frequently termed “polygenic 
disorders” (meaning many genes) or 
“multifactorial diseases” (meaning 
caused by a combination of genetic 
and environmental factors). 
In addition, some mutations are 
linked only to a heightened risk, not 
a certainty, of disease. For example, 
women who carry a mutation in 
the BRCA1 or BRCA2 gene have a 
more than 80 percent increased risk 
of developing breast cancer by age 
70, as well as an increased risk for 
Normal Male Chromosomes
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ovarian cancer. But it is not certain 
that they will develop any cancer.  
Men with a mutation in one of these 
genes are at increased risk for breast, 
prostate and other cancers.  
Furthermore, a genetic mutation 
does not necessarily predict the 
severity of a disease if it does occur. 
Two people with the same disease-
causing mutation can have widely 
diff ering prognoses.  Additionally, 
even when there is a complete 
correlation between having a 
mutation and developing a disease, 
such as in the case of the mutation 
linked to Huntington disease, the 
genetic test cannot predict when 
in the person’s life the disease will 
manifest itself.  
Th ese inherent limitations 
mean that although genetic testing 
provides additional precision to 
modern medical diagnosis it also 
introduces new uncertainties.  
Although a test can determine the 
presence of a mutation with certainty 
it cannot with certainty predict the 
outcome of having that mutation. 
Genetic disease risks are frequently 
stated in terms of probabilities, and 
that can lead to the need to make 
diffi  cult health care choices in the 
absence of defi nitive information.
The Technology of Testing
Th e number of conditions for 
which genetic testing can be done is 
rapidly increasing at the same time 
that the technology has become ever 
more powerful.  Historically, certain 
genetic diseases have been diagnosed 
through the use of biochemical 
tests.  For example, before the advent 
of a DNA-based test for Tay Sachs 
disease, both disease and carrier 
status could be identifi ed through 
a biochemical test, which revealed 
the level of the Tay Sachs-related 
protein.  Reduced level of the protein 
allowed the inference that there was 
a mutation in the gene sequence 
coding for that protein.    
DNA-based (molecular 
genetic) tests have largely replaced 
biochemical tests for a number of 
reasons.  For one, DNA is more 
readily available and is stable.  A 
DNA-based test can be done on 
virtually any cell in the body.  DNA-
based tests are oft en easier, less 
expensive, more accurate and faster 
than biochemical tests, allowing for 
more rapid results at a lower cost to 
the patient. 
Molecular tests to examine 
an individual gene require either 
probing for a particular mutation 
or variant or comparing the DNA 
sequence in a patient’s gene to that 
in a normal version. Tests can detect 
very small changes in the DNA, as 
small as a single DNA base pair.  
Th ere are genetic tests available 
or in development for over 1000 
diseases. Currently, not all genetic 
tests are generally off ered in the 
reproductive context.  But there is no 
technological barrier to introducing 
them as part of reproductive genetic 
testing.
Cytogenetics (chromosome 
analysis) assesses the number or 
structure of chromosomes present 
in the cells. Fluorescently labeled, 
chromosome-specifi c probes are 
used to visualize spots representing 
each copy of that chromosome. Too 






Family history or high incidence 
of disease in relevant population
Inform reproductive decision making, 
including whether to use PGD or 
prenatal genetic testing
Prenatal Genetic 
Testing Fetuses in utero
Increased risk identifi ed from 
carrier testing, family history, 
advanced maternal age, screening 
tests results
Give parents information, allowing them 
to prepare for birth of aff ected child, 






Increased risk identifi ed from 
carrier testing, family history, 
advanced maternal age 
Select embryos for transfer to avoid 
known risks, select particular  trait, or 
increase success of IVF
Reproductive Genetic Testing
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few or too many spots can indicate 
abnormalities.
Instead of looking for one DNA 
variation at a time, new “gene chip” 
technology can test for hundreds, 
even thousands, of possible DNA 
variations simultaneously.  In 
addition to detecting specifi c DNA 
mutations, gene chip technology 
is used to detect chromosome 
abnormalities or to measure the 
“expression” of genes, that is, which 
genes are turned on and off  and to 
what extent they are functioning. 
Carrier testing is typically 
performed on adults, either before 
they conceive or aft er conception, to 
see if they risk passing a mutation 
to their child. All that is required 
is a small sample of DNA, which 
is typically obtained from a blood 
sample or a swab taken from inside 
the cheek. 
Prenatal genetic testing is 
done during pregnancy. Most 
oft en, this involves conducting 
tests on fetal cells obtained from 
fl uid surrounding the fetus 
(amniocentesis) or from fetal cells 
removed from the placenta (CVS). 
PGD is done on embryos that are 
created outside the womb through in 
vitro fertilization. One or two cells 
are removed from the embryo and 
tested for the presence of a particular 
genetic trait or condition.  Embryos 
with the desired characteristics are 
then transferred to a woman’s uterus.
Genetic testing is laboratory  analysis of DNA, RNA, or chromosomes.  Testing 
can also involve analysis of proteins or metabolites that are the products of 
genes. Genetic testing is done to predict risk of disease, screen newborns 
for disease, identify carriers of genetic disease, establish prenatal or clinical 
diagnoses or prognoses and direct clinical care.  Testing can be done using 
many diff erent biological samples, including blood, amniotic fl uid (from 
which fetal cells are obtained) or individual embryonic cells.  Cytogenetic 
analysis is used to detect abnormalities in chromosomal number and/or 
structure, such as those that might indicate Down syndrome.  Molecular 
genetic testing examines individual genes. 
Data source: GeneTests database (2003)            
www.genetests.org
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Reproductive genetic testing 
off ers prospective parents 
information about their risk of 
having a child with a genetic 
disease.  Th is information can be 
used to help parents make profound 
decisions such as whether to pursue 
pregnancy at all; use donated eggs, 
sperm or embryos; seek additional 
testing; select specifi c embryos for 
transfer into the woman’s uterus; or 
decide whether to continue or end 
a pregnancy.  Reproductive genetic 
testing raises ethical, social and legal 
issues that cannot be resolved by 
science and technology alone.  
Reproductive genetic testing may 
help relieve anxiety by reassuring 
prospective parents that their risk 
is low for having a baby with a 
particular genetic disease or diseases. 
However, reproductive testing also 
may cause tremendous worry for 
some patients and family members.  
Patients sometimes do not fully 
understand what the tests mean and 
what decisions they will need to 
make based on the results.   Some 
observers worry about how the 
information obtained from testing 
will be used, particularly whether it 
will lead prospective parents to have 
an abortion or to selectively destroy 
embryos.  Others worry about the 
eff ect of genetic testing on the way 
we view each other and our children. 
And many ask who will have access 
to reproductive genetic testing, who 
pays for it and whether widespread 
reproductive genetic testing is an 
eff ective use of limited health care 
resources.
Given these concerns, people 
diff er about whether there should be 
limits on reproductive genetic 
testing, what those limits should be 
and who should set them.  
Perceiving Genes As Destiny
In the public’s mind, genetic 
testing is oft en viewed diff erently 
from other diagnostic tests and 
medical treatments.  Genetic 
tests, while not necessarily more 
informative than other medical tests, 
are oft en perceived as such. Genetic 
information carries with it an aura of 
immutability that other medical data 
do not.  Genetic testing gives people 
information — albeit sometimes 
uncertain information—about 
themselves or their family members.  
While these conditions may be 
treatable or manageable, the DNA 
itself cannot be altered, and genetic 
test results are therefore perceived 
as presenting a fi xed destiny.  As a 
result, many have raised concerns 
about the potential stigma of genetic 
information if it is used to a person’s 
disadvantage, for example by 
employers or insurers.
Genetic test results also may aff ect 
other family members and family 
relationships in a way other medical 
information does not.  Prospective 
parents may learn that they have a 
genetic mutation and have to decide 
whether to inform other family 
members who may also have the 
mutation. 
The Social Meaning of Genetic 
Difference  
A genetic test can only identify 
a particular DNA sequence or 
chromosomal abnormality. It cannot 
ascribe social signifi cance to that 
fi nding; only individuals and society 
can do that.  
Many Americans believe that 
certain diseases caused by genetic 
mutations, such as those that lead 
to suff ering and death in early 
childhood, are serious enough to 
justify testing and preventing the 
birth of an aff ected child.  However, 
the distinction between what is a 
“normal” genetic variation and what 
constitutes a “disease” is oft en not 
clear or agreed upon by society.  
Some fear that the availability 
of more genetic tests, combined 
with greater technological ease in 
performing them, will lead to people 
viewing genetic variation as either 
“diseased” or “desirable.”  As more 
people use genetic information to 
make reproductive choices, the 
tendency may be to classify mild 
disorders or natural variations 
as abnormal, leading to societal 
stigma and decreased tolerance and 
appreciation for human diff erence.  
Specifi c concerns also have been 
raised about the societal impact 
of using prenatal testing or PGD 
Genetic Testing and Issues for Society
“I think if  we as a society 
determine that we want to 
screen out disability and use 
genetic testing for that, we will 
have lost a great deal in terms 
of  the amazing contributions 
people who are labeled disabled 
can make. . . . as well as to have 
really misunderstood what it 
means to be human.” 
Sharon Terry, Genetic Alliance *
* Quotations used in this report are from Chosen Children: Issues in 
Reproductive Testing (video), on fi le with Genetics and Public Policy Center
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to select traits viewed by some 
as more desirable.  For example, 
some oppose the use of prenatal 
testing or PGD to select sex when 
the purpose is to satisfy parental 
preferences and not to avoid X- or 
Y- linked disease. Historically, in 
many societies females have been 
subjected to discrimination based 
purely on gender. In some parts of 
the world, there are cultures that 
still openly prefer male children 
to female. In those cultures, some 
parents terminate a pregnancy if the 
fetus is known to be female. Given 
this history of discrimination and 
existing cultural preferences for boys, 
some observers see using PGD for 
sex selection as having the potential 
to devalue women.  However, 
others argue that in many countries, 
including the U.S., one sex is not 
currently preferred over the other 
and sex selection has been used to 
select boys and girls equally. 
Impact on Parents and Children
Some fear that as testing becomes 
available for an increasing array of 
inherited diseases and conditions, 
couples will face growing medical 
and societal pressure to avoid the 
birth of a child that has not “passed” 
all the requisite genetic tests. 
Th ese parents may feel they have 
no choice but to undergo invasive 
prenatal testing, taking unwanted 
risks with a wanted pregnancy.   
Others envision that the spread of 
carrier tests will create a climate 
in which those with “bad” genes 
will be discouraged from biological 
reproduction, or feel pressure to use 
PGD or prenatal diagnosis to avoid 
having a child with a genetic disease.  
Th e question remains whether the 
availability of reproductive genetic 
testing might lead to a decrease in 
resources and support for those 
living with disabilities, less money 
for treatments and cures for genetic 
diseases and a more negative 
societal attitude towards people with 
disabilities generally.
On the other hand, some have 
argued that the more widespread 
genetic testing becomes, and the 
more each individual knows about 
his or her genetic makeup and 
risk for particular diseases, the 
more society will tolerate human 
diff erences. Rather than expecting 
each fetus to meet some defi nition of 
genetically “normal,” the knowledge 
that no individual is a “perfect 
specimen” will lead to less pressure 
to use all available technology to 
have a “perfect” child.
Some also fear that reproductive 
genetic testing will change the way 
we view children. In the future, it is 
possible that parents could choose 
to transfer only those embryos 
possessing particular characteristics 
not related to health but viewed 
as socially advantageous, such as 
appearance.  Th ese observers say it 
is a natural, but troubling, human 
impulse to try to have a “perfect” 
child — whatever one defi nes 
“perfect” to be.  Th e argument is 
that if parents have the power to 
accept or reject an embryo or fetus 
based on its genetic characteristics, 
children will no longer be viewed 
predominantly as precious gift s 
to be loved unconditionally but 
as carefully selected collections of 
attributes chosen from conception to 
meet a parent’s expectations. 
Even now, with the reproductive 
testing already being done, there is 
concern that the large number of 
parents who terminate a pregnancy 
aft er learning the fetus has Down 
syndrome will make the condition 
so rare that children will be viewed 
as avoidable “mistakes” and their 
parents as irresponsible. 
On the other hand, others argue 
that a positive impact of testing will 
be to reduce the number of children 
with disabilities being born into 
families who are unable or unwilling 
to love them and care for them. 
“Children are not like a recipe, 
where you pick different things 
and you mix it up in a petri dish 
and  you come out with a  child 
that you expect on the other 
end.” 




“When you begin to do genetic 
testing . . . at the early stages, 
you are also on the way to 
saying that children have to . . . 
be able to climb over a certain 
genetic bar to be able to be 
entitled to get into the world and 
entitled to parental acceptance.”  
Leon Kass, American Enterprise 
Institute
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Some also point out that testing for 
Down syndrome has been available 
for decades and that during that 
time, society’s acceptance of people 
with disabilities has not decreased. 
Th e development of tests for 
genetic diseases or predispositions 
to genetic disease has far outpaced 
the development of methods to 
prevent or cure these conditions.  
Th at leads some, particularly pro-life 
individuals, to wonder whether it is 
a net benefi t or harm to know that 
one carries a particular disease-
causing genetic mutation when there 
is no viable treatment and where 
the “treatment” is to eliminate the 
“patient.” 
In addition, there is debate about 
whether it is appropriate to test 
fetuses or embryos for disorders, 
such as Huntington disease, that 
would not aff ect them for many 
years, during which time a treatment 
may be discovered. Debate also exists 
about the use of reproductive genetic 
tests that identify predisposition 
to, or increased risk of, developing 
a disease such as breast cancer, 
particularly when the disease itself 
is potentially treatable and even 
curable. At issue is how a life is 
determined “not worth living,” and 
the level of risk parents are willing 
to take.
The Changing Experience of 
Pregnancy
Th e proliferation of genetic testing 
before and during pregnancy has had 
a signifi cant eff ect on how women 
and their partners experience having 
children.  From the beginning, a 
woman considering pregnancy or 
a newly pregnant woman may be 
told that genetic testing is needed 
to determine whether she is at risk 
for carrying a fetus aff ected by a 
genetic disease.  Many of the early 
pregnancy visits to a provider may 
be spent in part discussing the 
choices of prenatal screening tests 
or more invasive testing.  Th en, 
weeks may go by when the woman 
is already pregnant and awaiting 
the results of testing.  Testing may 
lead to more testing, to decisions 
whether or not to terminate a fetus 
and to an overall heightened sense of 
anxiety.  While many individuals and 
couples appreciate the information 
and reassurance that testing can 
provide, some experience the 
process, if not the result, as too much 
information and too many choices.  
Th e Role of Genetic Counseling in Testing
Many providers recommend genetic counseling prior to testing. Genetic 
counseling may be done by certifi ed genetic counselors or geneticists or by 
other providers with appropriate expertise. Ideally, aft er reviewing medical 
and family histories, a genetic counselor or other provider assesses the specifi c 
genetic risks to a pregnancy and helps the patient through the decision-
making process about whether or not to undergo testing based on the parent’s 
own values and beliefs.
In the context  of reproductive genetic testing, the options for the family will 
be specifi c to the type of testing (whether carrier, prenatal or preimplatation), 
what is being tested for and whether treatment is available. Genetic counseling 
gives prospective parents the information necessary to make an informed 
decision. However, decisions made about whether to have genetic testing and 
what to do with the results should be determined solely by the parents-to-
be.
Referrals for genetic counseling are increasing. However not all genetic 
counseling services are available in all areas and many questions exist about 
whether and when these services are reimbursed by insurers.
Genetic Testing and Issues for Society
““Over the past 20 or 30 years 
there have been opportunities 
to terminate fetuses with Down 
syndrome and that has been 
going on for a generation 
and yet I don’t believe that 
individuals with mental 
retardation or with Down 
syndrome are any more or less 
excluded or that parents have 
the sense or society has the sense 
that this is a child that could 
have been or should have been 
prevented.” 
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Some observers note that even once 
pregnant, mothers-to-be may avoid 
feeling connected to the fetus and 
the pregnancy until they receive a 
“clean bill of health” from prenatal 
testing. 
Access to Care and Insurance
It is not certain whether and to 
what extent insurers cover carrier 
testing, prenatal screening and 
genetic testing, PGD and the genetic 
counseling that goes with testing.  
Th ere is signifi cant variation in both 
the specifi c tests plans cover and the 
detail available to enrollees about 
what is covered. 
In general, the longer a medical 
test or procedure has been in use the 
more likely it is to be covered.  Older 
technologies such as amniocentesis 
and CVS tend to be covered, while 
the newer technologies, such as 
fi rst-trimester screening, may not 
be covered because the insurer sees 
them as unproven and unnecessary.  
It is not clear how coverage of 
testing will be aff ected by the advent 
of gene chips and other high-
throughput “microarray” technology 
that can quickly detect a number of 
genetic variations in one test. While 
such methods could make testing 
cheaper overall, initially insurance 
companies are likely to be skeptical 
of paying for an unproven, cutting-
edge technology.  Th e issue of what 
tests should be bundled together 
could be diffi  cult to resolve.
Bundles that include a wide range 
of known genetic indicators mean 
that insurance companies may have 
access to an increasing amount of 
information about an individual’s 
genetic makeup potentially even 
before birth.  Such information may 
include mutations indicating an 
increased likelihood (rather than a 
certainty) of developing a disease 
either in childhood or in adulthood.  
Many observers have raised concerns 
about discrimination on the basis 
of a person’s genetic makeup by 
insurers and employers, and these 
concerns could create a barrier to 
testing for patients.  
The Moral Standing of Embryos 
and Fetuses
Reproductive genetic testing is 
inextricably bound to the intense 
and oft en divisive discussion within 
our society about the status and 
respect that should be aff orded to 
human life at diff erent stages of 
development, and when, if ever, 
having an abortion or destroying 
or discarding an embryo should be 
considered justifi ed or acceptable. 
Americans have deeply held—yet not 
necessarily rigid—views about the 
moral standing of both the human 
fetus and the embryo. Reproductive 
genetic testing invariably taps into 
other, sometimes confl icting values 
and beliefs.  And those beliefs 
infl uence perspectives about various 
forms of reproductive genetic tests. 
But with a wide range of ethical 
complexities and choices, the issues 
raised by reproductive technologies 
are sometimes colored in shades of 
gray rather than black and white.
The Role of Religion
Many prospective parents turn to 
their religious tradition or individual 
clergy for guidance in decisions 
about the use of reproductive 
genetic technologies.  However, 
many religions are just beginning to 
grapple with these issues.  For some 
religions, acceptability depends on 
the specifi c technology and how the 
information it provides will be used.  
For example, some religions fi nd that 
prenatal testing that ends in abortion 
or testing of human embryos goes 
against their faith but that carrier 
testing to consider one’s risk of 
having off spring with a genetic 
disease is acceptable.  Other religions 
rely on  case-by-case determinations 
that consider the circumstances and 
personal beliefs of the couple and 
the potential impact on the family of 
having a child with a serious disease.  
Not surprisingly, there is a rich 
diversity of religious perspectives on 
reproductive genetic testing. 
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Carrier testing is performed 
because an individual’s family history 
or racial or ethnic background 
indicate heightened risk of carrying a 
mutation for a particular autosomal 
recessive (non sex-linked) disorder.  
In autosomal recessive disorders, a 
person must have two copies of the 
mutation to be aff ected.  Individuals 
who carry one copy of the alteration 
are carriers and typically show no 
signs of the disease. When both 
parents are carriers, there is a one 
in four, or 25 percent, risk for each 
child to inherit the mutation from 
both parents and be aff ected.
Examples of disorders for which 
carrier testing can be done in 
specifi c populations include cystic 
fi brosis (CF) in Caucasians, sickle 
cell disease in African Americans, 
thalassemia in Asians and 
individuals of Mediterranean descent 
and Tay Sachs and Canavan disease 
in Ashkenazi Jews. 
One important limitation of some 
carrier tests is that it may not detect 
every disease-causing mutation in 
a gene.  For example, more than 
1000 mutations that can cause cystic 
fi brosis have been identifi ed. Th e 
recommended carrier test panel 
for cystic fi brosis is pan-ethnic and 
includes 23 of the most common 
mutations and four refl ex tests that 
are used to clarify or elaborate initial 
test results. In addition, since the 
frequency of diff erent mutations 
varies among population groups, the 
detection rate of the test panel will 
vary by group. But those who carry 
a rare mutation will not be identifi ed 
using the standard test.
Carrier testing may be used in 
several ways by prospective parents 
to make decisions about whether and 
how to have children.  Depending 
on the condition in question, at-risk 
couples may choose not to risk 
having a child born with a particular 
disorder and may adopt or use 
donated eggs, sperm or embryos.  
Some may go through in vitro 
fertilization and test the embryos 
using PGD to select unaff ected 
embryos for transfer into the 
woman’s uterus.  Others may decide 
to become pregnant and to pursue 
the earliest available prenatal testing.  
Some parents may use carrier testing 
to learn about their risks before they 
become pregnant but not pursue 
prenatal testing.
In addition to the carrier testing 
discussed above, it has become more 
common for adults to be tested 
for mutations linked to  late onset 
disorders and those that indicate 
increased risk, not certainty, of 
developing disease.  Th us more 
adults have undergone testing 
either for their own health or for 
reproductive planning, providing 
information about genetic risks that 
can be passed along.  Indeed, we 
can expect that in the future, young 
people entering reproductive age will 
know quite a bit about their genomes 
before even considering having a 
family.
Current Issues in Carrier Testing
Th e identifi cation of genetic 
mutations with higher prevalence in 
certain racial or ethnic groups has 
led to targeted, population-based 
carrier testing programs in the 
United States with widely varying 
results. Th ese experiences provide 
important lessons for the design of 
future genetic testing policies and 
programs.
Lessons from the Past
Tay Sachs: An Eff ective Use of 
Carrier Testing
 
Tay Sachs is an autosomal 
recessive disorder caused by a 
mutation in the gene that makes 
hexosaminadase A (hex A), a protein 
that is necessary to break down fatty 
substances in brain and nerve cells. 
Children who receive two copies 
of a mutation in the hex A gene 
deteriorate mentally and physically, 
eventually suff ering blindness, 
deafness and paralysis.  Th ere is 
no treatment available and the 
condition typically  leads to death by 
age fi ve. 
Tay Sachs disease occurs most 
frequently in descendants of Central 
and Eastern European (Ashkenazi) 
Jews. About one out of every 30 
American Jews is a carrier. Th e 
mutation is also more common in 
some non-Jewish individuals of 
French-Canadian ancestry (from 
the East St. Lawrence River Valley of 
Quebec), and members of the Cajun 
population in Louisiana.
 
Early carrier testing programs 
measured the amount of the hex 
A protein in the blood.  Since the 
Carrier testing is genetic testing to 
determine whether an individual 
carries one copy of an altered 
gene for a particular recessive 
condition.
Carrier Testing:
What it is and how it works 
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gene was identifi ed in the late 1980s, 
however, genetic testing has largely 
replaced the biochemical tests. 
Th e DNA-based test is also used 
for prenatal genetic diagnosis aft er 
amniocentesis or CVS and for PGD.  
Testing programs for Tay Sachs 
within the Ashkenazi Jewish 
population were fi rst established 
in the United States in 1971 and 
within fi ve years had extended to 52 
American cities and Canada.  Testing 
programs took place in a variety 
of settings, including synagogues, 
high schools and Jewish community 
centers.  Th ey were characterized 
by a high degree of collaboration 
between clinical researchers 
and community leaders.   At the 
same time, a voluntary quality 
assurance program was instituted 
for laboratories performing testing, 
under the auspices of the National 
Tay Sachs Association. 
Tay Sachs carrier testing programs 
in the Ashkenazi Jewish community 
have been cited as an example of 
a successful testing eff ort because 
they led to a dramatic decrease in 
the incidence of Tay Sachs in that 
population and because they were 
viewed positively by those targeted 
for testing.  Th ere has been little 
controversy within the community 
about the appropriateness of testing 
for the disease, in part because Tay 
Sachs is fatal in early childhood.  
Jews diff er in their views about 
abortion.  For example, Orthodox 
Judaism prohibits abortion under 
most circumstances, making 
preconception, and even premarital, 
testing preferable to prenatal 
testing.  One voluntary, anonymous 
premarital testing program is run by 
an organization called Dor Yeshorim, 
which primarily targets certain 
Orthodox communities where 
many marriages are arranged and 
where abortion is rarely permitted.  
Many individuals are tested while in 
school, and men and women who 
test positive as Tay Sachs carriers 
are not introduced to each other as 
potential mates.  If a couple submits 
for testing aft er they have begun 
dating, and they are both found to 
be carriers, they are counseled not to 
marry.
Carrier Frequency in Different Populations for Selected Single Gene Disorders
Condition Frequency in U.S. Population
All Caucasian Hispanic African American Asian American
Cystic fi brosis 1/31 1/29 1/46 1/65 1/90
Sickle cell ~1/17 1/12
Tay Sachs
All Ashkenazi Jewish Sephardic 
Jewish
French Canadian / 
Cajun
1/250 1/27  1/250  ~1/30 
Th alassemia1





1  includes both β-thalassemia and α-thalassemia 
2  this population is mostly aff ected by α-type thalassemia
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Sickle Cell: Carrier Testing Causes 
Concerns 
In contrast to the success of the 
Tay Sachs testing program, the 
establishment of testing programs 
for sickle cell anemia in the 1970s 
was marred by lack of collaboration 
between the community and 
those establishing the testing 
programs, and discrimination and 
misunderstanding regarding the 
health consequences of being a 
carrier.
Sickle cell anemia is an autosomal 
recessive disease caused by 
mutations in the beta hemoglobin 
gene that result in the malformation 
of red blood cells.  People with 
mutations in both copies of the 
beta hemoglobin gene experience 
symptoms including anemia, 
recurrent infections, pain and 
vascular complications that can lead 
to strokes and other serious medical 
problems. However, the severity of 
the disease is variable. Treatments 
exist to prevent and mitigate some 
of these symptoms, and have led 
to increased life expectancy.  Many 
people with sickle cell disease live 
into their 40s and beyond.  Carriers 
of sickle cell anemia — those who 
have only one copy of the mutation 
— experience no symptoms of the 
disease under most conditions.  
In the United States, most cases 
of sickle cell disease occur among 
African Americans and Hispanics 
of Caribbean ancestry. About one 
in every 500 African Americans has 
sickle cell disease and one in twelve 
is a carrier. 
Technical capacity for sickle 
cell carrier testing and interest in 
developing programs to identify 
carriers of the disease developed 
in the 1970s.  Medical geneticists 
saw testing for sickle cell carriers as 
providing benefi ts similar to those 
gained from Tay Sachs testing: 
identifi cation of carriers of a serious 
genetic disorder in a defi ned 
population to allow for informed 
reproductive decision making. 
Between 1971 and 1973, 
legislation related to sickle cell 
carrier testing was passed in 17 
states and the District of Columbia.  
In some states, carrier testing 
was mandated by law, rather than 
voluntary, and was generally targeted 
at African Americans.  Some states 
made testing a requirement for 
school entrance, giving the false 
impression that carrier status had 
a bearing on a child’s health.  Some 
employers used sickle cell testing to 
exclude carriers from certain jobs, 
and insurers used it as a basis to 
deny coverage.  On the federal level, 
Congress passed the National Sickle 
Cell Anemia Control Act in 1972, 
which provided funding for research, 
testing, counseling, education 
and treatment, and predicated 
such funding on voluntary testing 
programs.
Sickle cell carrier testing came to 
be viewed by many in the African 
American community as an eff ort 
by the white power structure to 
impose a stigmatizing genetic testing 
program on a minority population.  
Testing programs were usually 
administered by health departments 
composed of predominantly white 
medical personnel, contributing to 
the impression that testing was being 
imposed on the black community. 
Th e programs also were instituted 
against a backdrop of historical 
discrimination, eugenics and 
unfounded claims of black biological 
inferiority. Confusion between sickle 
cell disease and carrier status (which 
was historically called sickle cell 
“trait”) among physicians, the public 
and policymakers created a false 
perception that being a carrier was a 
health risk. 
Currently, sickle cell carrier 
testing programs in the United 
States exist on a voluntary basis, 
and testing is recommended by the 
American College of Obstetricians 
and Gynecologists (ACOG) for all 
couples at increased risk for having 
children with sickle cell anemia. 
High-risk groups include people of 
African American, Southeast Asian 
or Mediterranean ancestry. 
“Until we are able to give 
everyone access to do something 
about a problem, those 
people who have historically 
been disadvantaged in our 
society . . . either as a result 
of  minority status or because 
of  socio-economic conditions 
are certainly going to be 
disadvantaged and undoubtedly 
look with skepticism [on these 
technologies].” 
Patricia King, Georgetown 
University Law Center
Carrier Testing
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Sickle cell carrier testing 
continues to take place; however, 
some data indicate that relatively 
few at-risk couples choose prenatal 
diagnosis to detect the disease 
in a fetus.  Similarly, relatively 
few couples choose to terminate 
a pregnancy if the fetus is found 
to have the disease. Th e reasons 
for these choices are many. Some 
couples lack access to early prenatal 
care and thus may miss the 
opportunity for prenatal testing.  
Others may choose not to test 
because the disease is treatable and 
has a variable and unpredictable 
severity.  Individual and cultural 
attitudes about children and abortion 
more generally also may play a role.  
Cystic Fibrosis: Th e Push for Broad 
Testing
Cystic fi brosis carrier testing is the 
most recent and most far-reaching 
carrier testing program in the United 
States.  In contrast to Tay Sachs and 
sickle cell anemia, the decision to 
off er population-based testing was 
preceded by more than a decade of 
discussion and consensus-building 
within the genetics community and 
professional organizations. While it 
is too soon to tell how this testing 
eff ort will fare, certain concerns 
already have appeared.
Cystic fi brosis is an autosomal 
recessive disorder that aff ects 
the respiratory, digestive and 
reproductive systems. It is one of 
the most common genetic diseases 
among people of northern European 
descent. Th e carrier frequency in 
white Americans is 1 in 29.  In 
contrast, carrier frequency in 
African Americans is 1 in 65, and in 
Asian Americans it is 1 in 90. While 
historically CF almost invariably led 
to death from pulmonary disease 
in early childhood, advances in 
treatment over the last 30 years 
have led to improvements in life 
expectancy. Median survival is now 
33.4 years.  Th e course of the disease 
is variable, with some individuals 
suff ering signifi cant morbidity 
such as frequent lung infections 
and diffi  culty breathing, and others 
having more mild symptoms.
Identifi cation of the most 
common mutation causing CF in 
1989 led to interest in population-
based carrier testing.  But, as more 
mutations were identifi ed — to 
date over 1000 have been identifi ed 
— scientists realized that carrier 
testing would be complicated.
In 1997, the National Institutes 
of Health convened a panel to 
consider CF carrier testing.  Th e 
panel, which included scientists, 
physicians, bioethicists and 
economists, recommended that 
CF carrier testing be off ered to all 
individuals with a family history 
of CF and their partners, as well 
as to anyone pregnant or planning 
a pregnancy, particularly those in 
high-risk populations.  In 2001, 
ACOG and the American College of 
Medical Genetics (ACMG) issued 
recommendations that CF carrier 
testing be “off ered” to non-Jewish 
Caucasians and Ashkenazi Jews, 
and “made available” to other 
ethnic and racial groups. Th ese 
guidelines, however, did not clarify 
the operational distinction between 
“off ering” a test and “making it 
available” in clinical practice. 
Th ere have been anecdotal reports 
relating to incorrect performance 
and reporting of test results by 
laboratories not following the 
ACOG/ACMG guidelines, incorrect 
interpretation of results by providers 
and failure to get informed consent.  
Some evidence suggests that 
unnecessary amniocenteses may 
have been performed as a result 
and there have been unconfi rmed 
reports that some women may have 
terminated pregnancies based on 
the false belief that their child would 
have CF.
Clearly, implementation 
of widespread carrier testing 
Th e Preconception Care Challenge
Many women are unaware of the genetic tests available to them or of the 
implications of test results to their reproductive decision making. Providers 
typically do not discuss reproductive genetic risk factors until aft er a woman 
is already pregnant.  But testing before pregnancy begins increases a woman’s 
reproductive options. Providers need to assess reproductive risks based on 
age, family history and ethnic background during routine visits and to discuss 
appropriate testing options with patients and patients, in turn, need to know 
to ask their providers about their reproductive risks on routine visits.  Private 
and public payors need to recognize the value of covering genetic counseling 
and testing services prior to pregnancy.  A public information or consumer 
campaign would help individual patients know what to ask their providers 
before initiating a pregnancy.
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recommendations, such as those for 
cystic fi brosis, can be challenging.  
For a variety of reasons, providers 
are oft en slow to follow new 
guidelines in practice.  
Th ese three historic examples 
merit careful evaluation and are 
instructive for future carrier testing 
eff orts.  Four lessons in particular 
stand out: (1) the importance of 
scientifi c and community consensus 
regarding the development and use 
of a test; (2) the value of community 
participation in determining the 
context of testing; (3) the need for 
ongoing monitoring and evaluation 
of test implementation; and (4) the 
importance of responding to new 
developments as testing evolves.
Timing of Carrier Testing 
Professional guidelines generally 
recommend that, when possible, 
carrier testing should take place 
before pregnancy occurs.  Testing 
before pregnancy provides 
prospective parents with information 
about their risks of having a child 
with a genetic disease, allowing them 
to consider reproductive alternatives. 
But there is evidence to suggest 
that, in practice, carrier testing is 
in most cases off ered to women or 
their partners aft er a pregnancy 
begins.  For example, according to a 
study published in 2004 by ACOG, 
almost one-half of obstetrician-
gynecologists do not ask non-
pregnant patients about their family 
history of cystic fi brosis, provide 
them with information about cystic 
fi brosis carrier testing or routinely 
off er carrier testing to patients 
who are not yet pregnant.  Many 
providers view genetic tests for 
patients who are not pregnant as 
less urgent and something that also 
would add time and paperwork 
to the patient encounter.  Patients 
may also not be interested in carrier 
testing until they are pregnant.  
Finally, providers and patients are 
oft en unsure whether and under 
what circumstances insurers will 
reimburse for carrier testing prior to 
pregnancy.  Insurers are inconsistent 
in this area, even though guidelines 
clearly recommend that testing be 
off ered. 
Other factors could prevent a 
couple from obtaining carrier testing 
prior to pregnancy.  Some research 
has showed that as many as one-
third to one-half of pregnancies 
are unplanned.  In addition, many 
women considering getting pregnant 
may not discuss their plans with 
their health care provider. Some 
women, particularly those who do 
not have health insurance or who 
have limited access to care, do not 
see a provider until the second-
trimester of pregnancy or later, 
further limiting their options.
Th ere are opportunities for 
off ering carrier testing to women of 
reproductive age during a routine 
visit.  For example, according to 
the Centers for Disease Control 
and Prevention (CDC), over 95 
percent of women between 18 and 
39 have had a pap smear in the past 
three years.  Th erefore, there is an 
opportunity in place for providers to 
discuss carrier testing during these 
visits.  
Finally, a number of issues related 
to communication of information 
aff ect carrier testing. For example, 
carrier testing oft en is presented 
as routine, but sometimes patients 
are unsure what tests they are 
receiving.  Oft en, testing laboratories 
group tests for mutations in several 
diff erent genes in a “panel” for 
effi  ciency, but the provider may not 
explain every test to the patient. In 
addition, providers may not know 
how to interpret or communicate the 
results of a carrier test even if they 
know when to off er it.  Th is may be 
because of the way test results are 
communicated by some laboratories 
or because of providers’ limited 
training in genetics or genetic 
counseling. 
Carrier Testing
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Prenatal testing includes 
prenatal screening to identify 
fetuses at higher risk for genetic or 
other abnormalities and prenatal 
genetic testing to diagnose genetic 
abnormalities in utero.  Test results 
may be used to help parents prepare 
for the birth of that child or make 
a decision about terminating the 
pregnancy. Th is section will focus on 
the use of these tests and procedures 
and the issues raised by their use.
Prenatal Screening
Prenatal screening includes a 
variety of technologies that identify 
those fetuses that have an increased 
likelihood of having genetic or other 
abnormalities.
Ultrasound uses high frequency 
sound waves to obtain an image 
of the fetus in utero. It is routinely 
used to determine fetal viability, 
the number of fetuses present and 
the position of the fetus and to 
estimate fetal age.  Sex may also be 
determined depending on the age 
and position of the fetus.  Some 
fetal malformations can be detected 
by ultrasound in utero, such as 
neural tube defects and some heart 
malformations. 
Maternal serum screening 
measures levels of fetal proteins 
circulating in the mother’s blood.  
Physicians now commonly screen for 
three or four proteins in the mother’s 
blood (called either a triple screen 
or a quadruple screen) to screen for 
birth defects such as neural tube 
defects or certain chromosomal 
abnormalities such as Down 
syndrome and trisomy 18. Typically, 
maternal serum screening is done 
around 15 to 20 weeks gestation, in 
the second-trimester of pregnancy. If 
screening results indicate abnormal 
protein levels, counseling about 
prenatal diagnosis is recommended.  
About 75 percent of pregnancies 
in which the baby has Down 
syndrome can be detected with 
the second-trimester screening. 
Maternal serum screening detects 80 
to 85 percent of babies with  spina 
bifi da and essentially all babies with 
anencephaly.  However, there are 
signifi cant false positive and false 
negative rates. 
First-trimester screening is a new 
option that is increasingly used but is 
not yet widely available in the United 
States. It uses the combination of a 
fi rst-trimester ultrasound and  serum 
screening to assess fetal risk of Down 
syndrome or other chromosomal 
abnormalities.  A specially trained 
physician or sonographer performs 
an ultrasound at approximately 11-
13 weeks of pregnancy to measure 
the nuchal fold translucency, which 
refers to the thickness of the fl uid-
fi lled space at the back of the fetus’ 
neck. Increased thickness indicates 
a heightened risk of chromosomal 
disorders including Down syndrome 
or trisomy 18.  In addition, the 
woman’s blood is tested for two 
pregnancy-related proteins, whose 
presence in abnormal levels can also 
indicate heightened risk for these 
disorders.  Th e laboratory results, the 
ultrasound measurements and the 
woman’s age are used to calculate her 
risk. 
In the case of Down syndrome, 
researchers have reported that fi rst-
trimester screening can identify 
more than 80 percent of aff ected 
fetuses. In addition to some aff ected 
fetuses not being detected with fi rst-
trimester screening (false negatives), 
there is a fi ve percent false positive 
rate (meaning that an unaff ected 
fetus is identifi ed as aff ected).
Th e advantage of fi rst-trimester 
screening is that a normal result 
provides earlier reassurance and an 
abnormal result allows the option of 
early diagnostic tests.
Diagnostic tests and procedures 
Prenatal genetic testing of a 
fetus requires two steps: an invasive 
procedure (amniocentesis or CVS) 
to obtain fetal genetic material 
and an analysis of the material 
to identify genetic abnormalities 
or characteristics.  Fetuses may 
be at increased risk for genetic 
abnormalities because of the 
mother’s age (35 or greater at 
delivery), because the parents 
already have a child or other family 
member with a genetic condition, 
because one parent has a balanced 
chromosome rearrangement or 
because prenatal screening or carrier 
testing indicates an increased risk.  
Prenatal screening includes those tests and procedures used to assess fetal 
risk for an abnormality, including genetic disorders. It does not provide a 
defi nitive diagnosis of a genetic abnormality.
Prenatal genetic testing  (or prenatal genetic diagnosis) is genetic testing of 
fetal cells obtained through procedures such as amniocentesis and CVS.
Prenatal Testing
What it is and how it works
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Amniocentesis is usually 
performed in the second-trimester 
of pregnancy, at approximately 15-
20 weeks gestation. A thin needle 
removes a small quantity of amniotic 
fl uid from the sac that holds the 
developing fetus. Th e fl uid contains 
fetal cells that provide the material 
for genetic analysis.
Amniocentesis is generally 
considered a relatively simple and 
safe procedure when performed by 
an experienced physician. Although 
miscarriage aft er amniocentesis is 
infrequent (one in 200-400 cases), 
it is a major reason the procedure is 
not routinely off ered to all women. 
Infection and leakage of amniotic 
fl uid are other possible complications 
of amniocentesis. 
Amniocentesis is not usually 
performed until the second-
trimester because most providers 
consider performing the procedure 
earlier too risky. Th us, one drawback 
of amniocentesis is that by the time 
results are available the pregnancy 
may have progressed 16 weeks or 
more.  
Chorionic villus sampling is 
an alternative to amniocentesis, 
and can be performed during the 
fi rst-trimester of pregnancy.  Fetal 
cells are obtained through biopsy 
of the chorionic villi — the cells 
that will become the placenta. CVS 
is generally done at 10-13 weeks 
gestation.  Fewer physicians do CVS 
than amniocentesis, and as a result, 
it is not available in all areas.  Th e 
risk of miscarriage aft er CVS is 
approximately 1 in 100, as compared 
with the 1/200-400 risk following 
amniocentesis.
CVS can be used to determine all 
disorders that can be diagnosed by 
amniocentesis except the presence of 
neural tube defects, since CVS does 
not include analysis of amniotic fl uid 
alpha-fetoprotein. 
Current Issues in Prenatal 
Screening and Testing
Th e Experience of Testing
Many factors go into an 
individual’s decision to obtain 
prenatal screening or prenatal 
genetic testing.  Screening and 
testing provide information; they 
do not dictate a course of action.  
Prospective parents can use this 
information to guide decisions about 
additional testing, prepare for the 
birth of a child with a genetic disease 
or as a basis to end the pregnancy.
People diff er in their desire to 
obtain information about the future 
— some may fi nd it reassuring, while 
others consider it unnecessary or 
simply nerve-wracking.  
For some, the actions they 
will or will not take based on the 
information dictate whether to test 
at all.  Some people who would not 
terminate a pregnancy irrespective of 
the test results decline testing on that 
basis.  Others may decline testing 
because they prefer to welcome 
the child fi rst, and then address 
any health problems the child may 
have.  For them, prenatal testing may 
seem intrusive and unnecessarily 
worrisome.  
Others may want to know 
test results, even if they would 
not terminate.  For them, the 
information allows them to 
prepare emotionally, medically 
and economically, and allows for 
appropriate medical support at the 
time of the birth.  For these people, 
knowing as much as possible about 
the health of the fetus, as early in the 
pregnancy as possible, is of primary 
interest.   
For couples who would consider 
abortion in case of a serious genetic 
disease, information about the 
disease and the prognosis helps them 
make the decision whether or not 
to terminate the pregnancy.  Most 
would prefer that decision be made 
as early in the pregnancy as possible.
“I think there is a popular myth 
that information is value neutral 
and that . . . more information 
is necessarily a good thing.  
But with information comes 
responsibility.” 
C. Ben Mitchell, Trinity 
Evangelical Divinity School  
“Many couples at high risk for a 
child with a disease will choose 
to have the testing done to 
prepare themselves . . . we ought 
to separate in our minds genetic 
testing and what to do about 
[the information].” 
Francis Collins, National 
Human Genome Research 
Institute 
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Some people make their decisions 
about prenatal testing based on 
their perceptions of the risk of 
having an aff ected child, views about 
how diffi  cult it would be to raise a 
child with a disability, or previous 
experience with the disorder.  Family 
size, fi nancial circumstances and 
basic access to health care also may 
play a role in decision making, as 
may perception of the accuracy 
of test results and fear that the 
information learned could be used 
to discriminate against them.  Some 
may also worry about the small 
but real risk of miscarriage from 
amniocentesis or CVS. 
Th ere are probably as many 
reasons to undergo prenatal testing 
— or to refuse it  — as there are 
parents.  Yet whether someone will 
ultimately accept or decline testing, 
and what course of action they 
will take based on the information 
testing provides, is impossible to 
predict.
Sometimes women do not have 
the chance to consider prenatal 
testing.  Th ey may not see a health 
care provider until the pregnancy 
is too far along for some forms 
of prenatal screening and testing.  
Some women do not know they 
are pregnant — or do not want to 
be and therefore do not seek early 
prenatal care, even if they ultimately 
carry the pregnancy to term.  Some 
lack insurance or the means to get 
to a provider or clinic that they can 
aff ord.  
  
Some observers have raised 
questions about the impact of 
prenatal genetic testing on society 
and whether society should try 
to control its use. Some believe 
it should always be an individual 
parent’s choice about whether to 
seek screening and testing. By 
contrast, others argue that the 
individual choice argument fails 
to give adequate weight to how 
prenatal screening and testing may 
be profoundly changing the way we, 
as a society, view procreation and 
children. 
Furthermore, as screening and 
testing become easier, earlier, 
cheaper and capable of detecting 
a broader range of conditions, the 
concern is that society will see 
reproductive testing as the “right” 
thing to do.  Th erefore, the failure to 
test will be viewed as unacceptable. 
People who do not test — and 
perhaps even those who do but do 
not have an abortion when a test 
shows a genetic problem — could 
be stigmatized as irresponsible, and 
children born with genetic diseases 
could be seen as avoidable mistakes.  
How Tests And Results Are 
Provided 
Some observers are concerned 
about how information about 
prenatal genetic screening and 
testing is delivered to patients.  
Th is information is conveyed in 
a variety of settings and contexts.  
Sometimes it is a physician who 
discusses prenatal testing with 
the patient, sometimes a nurse or 
midwife and sometimes a patient 
is referred to a genetic counselor. 
Providers have varying levels of 
knowledge and comfort discussing 
these issues, and oft en very little 
time in which to cover all of 
the information adequately.  In 
some settings, a patient may be 
given an informational pamphlet 
about the most common forms of 
prenatal testing, such as maternal 
serum screening, and off ered the 
opportunity to ask questions, while 
in other settings a dialogue between 
health care professional and patient 
takes place. But in the course of 
most medical examinations, only 
a few minutes are spent discussing 
genetic testing. Th us, patients 
may end up making decisions 
based on incomplete or inaccurate 
information. Some may proceed with 
testing without fully considering the 
decisions they may have to make 
depending on the results of the tests.
Patients sometimes report feeling 
pressured by health care providers 
to agree to testing.  Health care 
providers may present these tests as 
routine, just like all the other tests 
one gets during pregnancy.  For 
example, little time may be devoted 
to discussing what a woman would 
actually do if told her maternal 
serum screening test came back 
abnormal, and thus she may 
suddenly fi nd herself facing diffi  cult 
decisions about more invasive 
testing.
Prenatal Testing
“There are a lot of  children 
who are born who, you can’t 
say it in polite company, but 
silently, people say, ‘if  only these 
people had done what they were 
supposed to do, these children 
wouldn’t be here.’” 
Leon Kass, American Enterprise 
Institute
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Another issue is whether there 
are economic, cultural, language 
or other factors that infl uence 
who is off ered or receives testing.  
Diff erences in access to testing may 
refl ect troubling underlying societal 
problems, such as inequitable 
distribution of health care resources, 
counseling that is not sensitive to 
cultural diff erences or mistrust 
based on historical experiences of 
discrimination.
Additional concerns have been 
raised about how test results are 
conveyed and how providers 
infl uence decision making once the 
parents have learned that a fetus is 
aff ected by genetic disease.  Some 
disability advocates have claimed 
that providers who discuss prenatal 
screening and testing describe 
conditions in the most extreme 
clinical terms and assume that 
parents will want to terminate an 
aff ected fetus.  Th ese critics say 
that providers are predisposed to 
counsel in favor of that decision, 
without giving suffi  cient context to 
the prospective parents about what it 
would actually be like to raise a child 
with the particular disorder.  Indeed, 
those aff ected with a particular 
genetic disorder sometimes view it 
as far less disabling than unaff ected 
people.
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Preimplantation genetic diagnosis 
(PGD) is a process in which embryos 
developed outside the womb 
are tested for particular genetic 
characteristics, usually genetic 
abnormalities that cause serious 
disease, before being transferred 
to a woman’s uterus. Whereas 
prenatal diagnosis can detect genetic 
abnormalities in a human fetus in 
utero, PGD off ers genetic testing 
before pregnancy begins. 
PGD has emerged from a 
convergence of two technologies 
— in vitro fertilization (IVF) and 
genetic testing. As genetic research 
has progressed, so too has work on 
IVF. In 1978, scientists achieved the 
fi rst viable human pregnancy from 
an egg fertilized outside the womb in 
a petri dish, or in vitro. Eventually, 
scientists developed methods to 
perform genetic tests on single cells 
taken from an early embryo. 
Th is new area of reproductive 
genetics, PGD, permits doctors and 
prospective parents to select embryos 
for transfer to the womb that do 
not have a genetic abnormality 
associated with a specifi c disease or, 
alternatively, that possess a genetic 
characteristic deemed desirable.
In the more than ten years 
since PGD was fi rst made 
available to facilitate embryo 
selection, over 1,000 babies have 
been born worldwide following 
a preimplantation genetic test. 
Inherited chromosome abnormalities 
and single gene disorders including 
cystic fi brosis, Tay Sachs disease, 
muscular dystrophy, sickle cell 
anemia and many others have been 
detected with PGD.  In theory, any 
of the hundreds of genetic tests now 
commercially available, and the 
many more in development, could be 
used to test embryos.
Preimplantation Genetic Diagnosis
What it is and how it works 
Genetic testing in PGD can be done by testing one or both polar 
body cells (2 & 3) that are cast off from the egg as it matures 
and is fertilized, or by testing cells from the embryo (4).
1.  Genetic testing in PGD starts with knowing the genetic 
makeup of one or both parents (only the egg is shown in 1). 
2.  Genetic testing of Polar Body I allows inference about the 
genetic composition of the egg. In this example, two copies 
of “C” are detected in the polar body inferring that the egg 
carries two copies of “A”. If “A” was the desired copy of the 
gene, this egg could be used for fertilization. If not, it would be 
discarded.
3.  Testing Polar Bodies I and II simultaneously after 
fertilization is another approach to polar body testing. In this 
example, two copies of “C” are detected in Polar Body I and 
one copy of “A” in Polar Body II, inferring that the fertilized egg 
contains one copy of “A”.
4.  More typically, PGD involves testing one or two cells of the 
embryo removed 2-3 days after fertilization when 5-8 cells are 
present. This permits direct analysis of the embryo’s genes. In 
this example, “A” and “T” are detected in the cell.
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Compared to carrier testing 
and prenatal screening and testing, 
PGD is much newer and much less 
common.  Nevertheless, PGD is 
becoming much more widely known 
and used, with some predicting 
that every couple using IVF will 
someday be off ered PGD in order 
to boost their success rates.  PGD 
sounds futuristic, but it is here and 
now, in use and subject to animated 
discussions both in favor and 
against.  Th us in a sense, PGD shines 
a bright light on how society reacts 
to and deals with new reproductive 
genetic technologies.
The Mechanics of PGD
PGD is a multi-step process 
involving egg extraction, in vitro 
fertilization, cell biopsy, genetic 
analysis and embryo transfer. 
First, as in all in vitro fertilization 
processes, eggs removed from the 
mother aft er she has been given 
drugs to stimulate egg production 
are fertilized in the laboratory. Th e 
genetic material for testing can be 
obtained in two ways. Th e most 
common method is to use one or 
two cells taken from an embryo 
two to four days aft er fertilization. 
Alternatively, genetic tests can be 
performed on cells (called polar 
body cells) that are cast off  by the 
egg as it matures and is fertilized. 
Th e results of the genetic tests on 
the polar bodies are used to infer the 
genetic makeup of the fertilized egg. 
Two techniques are used to 
analyze the genetic material from 
single cells: chromosomal analysis 
to assess the number or structure of 
chromosomes and DNA analysis to 
detect specifi c gene mutations. For 
chromosomal analysis, fl uorescently 
labeled, chromosome-specifi c 
probes are used to visualize spots 
representing each copy of that 
chromosome present in the cell. Too 
few or too many spots can indicate 
abnormalities. For direct DNA 
analysis, a technique known as a 
polymerase chain reaction (PCR) 
is used to make many copies of 
the targeted gene, which are then 
examined for evidence of a specifi c 
DNA sequence. 
Regardless of the methods, the 
results of preimplantation genetic 
diagnosis are used to inform the 
selection of embryos for transfer to a 
woman’s uterus. 
Current Issues In PGD
PGD was initially developed 
to identify and avoid specifi c 
disease-causing mutations prior 
to pregnancy.  More recently it has 
also been used as an adjunct to 
standard IVF to detect chromosomal 
abnormalities, called aneuploidy, 
arising during egg or embryo 
development. Th ere is some 
evidence that transferring only 
chromosomally normal embryos 
can boost the success rate of IVF 
procedures.  Some providers 
recommend PGD for all IVF patients 
over 35 or those with repeated IVF 
failure. Aneuploidy screening already 
accounts for the majority of PGD 
procedures and since one percent 
of all births in the United States are 
babies born as a result of IVF, there 
is the potential for continued steep 
growth in the use of PGD.
Other current applications of 
the technology that have generated 
controversy include using PGD 
(1) to select an embryo that is an 
immunological match to a sick 
sibling so the resulting child can 
be a stem cell donor, (2) to select 
the sex of an embryo purely for 
gender preference — that is, in the 
absence of a sex-linked disease risk 
— and (3) to test embryos for gene 
mutations associated with adult 
onset diseases such as Alzheimer 
disease or mutations that indicate 
a heightened but uncertain risk of 
developing a particular disease, such 
as hereditary breast cancer.
Th ere are alternatives to PGD. 
Prospective parents at risk of 
“Children have a right to be 
born as healthy as we can make 
them. We can’t guarantee that 
they will be healthy, even if  we 
do all things possible, but we 
should try to avoid those things 
that might cause them to be 
unhealthy.” 
Robert Murray, Howard 
University 
What PGD is Not
PGD should not be confused with 
gene therapy or any other eff orts 
to alter an embryo or a person’s 
genetic makeup.  PGD as currently 
practiced can reveal a considerable 
amount of information about an 
embryo’s genetic makeup, but it 
is not possible today to correct or 
alter an embryo’s genes.
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passing a genetic condition to 
their off spring can choose to avoid 
pregnancy, conceive using donor 
egg or sperm from an individual 
who does not carry the mutation in 
question, proceed with a pregnancy 
but undergo a prenatal diagnostic 
test and possibly terminate the 
pregnancy if it reveals a genetic 
abnormality or accept the possibility 
that their child could be born with a 
genetic abnormality. 
PGD is a powerful tool that 
may allow parents to identify and 
select only those embryos that 
possess the genetic characteristics 
they desire in their children. PGD 
cannot, however, create new genetic 
characteristics that neither parent 
possesses. PGD can allow parents 
to select only among the genetic 
combinations present in the embryos 
they have produced. 
Since PGD requires IVF, it is 
mainly used today by parents who 
are willing to undergo IVF to avoid 
a known serious or fatal genetic 
condition or who are unable to get 
pregnant without IVF because of 
infertility problems. For the moment, 
one would expect very few people 
who otherwise have no problems 
achieving a healthy pregnancy to 
utilize PGD. Nonetheless, that could 
change as IVF techniques improve 
and the number of genetic tests that 
can be employed successfully in 
PGD increases. 
For families at high risk of a 
genetic disorder, PGD may increase 
their chance to bear a healthy child.  
Similarly, for parents with a child 
who suff ers from a disease treatable 
with donor tissue, the use of PGD 
to produce a genetically-matched 
sibling may be the only way to save 
their child’s life.  And, for women 
with repeated miscarriages and IVF 
failures, PGD may be their best hope 
for a successful pregnancy.
Some see ethical issues arising 
from the use of PGD to test embryos 
for aneuploidy in order to improve 
IVF success rates.  Parents who have 
enough embryos that are considered 
genetically good candidates for 
transfer may be asked whether they 
want a boy or girl, or — possibly in 
the future — a child who is tall or 
short, blond or brunette.  By giving 
prospective parents the opportunity 
to choose among embryos, PGD is 
arguably the form of reproductive 
genetic testing that gives parents the 
greatest power to predetermine the 
genetic characteristics of children.  
For those who categorically 
oppose manipulation or destruction 
of human embryos, PGD is never 
appropriate because it necessarily 
involves one or both. Some in this 
group would favor a ban on the 
technology, while others would not 
support a policy that would prevent 
others from using the technology, 
even if they would not use it 
themselves.
Many people, including some who 
are troubled by the manipulation 
or destruction of embryos may 
nevertheless support PGD when 
it is used to detect certain serious 
medical conditions but have 
reservations about its use for other 
purposes. 
For others, concerns arise not 
from the status of the embryo but 
from the potential safety of the 
procedure for women and the 
resulting children.  Th ere are many 
unanswered questions about the 
long-term consequences of PGD and 
IVF.
Some observers view PGD, or 
any technology that allows parents 
the ability to choose their children’s 
characteristics, as potentially 
altering the way we view human 
reproduction and our off spring in a 
fundamental way. Th ey worry that 
human reproduction could come 
to be seen as within the realm of 
technology and children the end 
result of a series of meticulous, 
technology-driven choices.
Others argue that widespread use 
of PGD could exacerbate existing 
societal inequalities if some have 
the means to select their children 
for a range of “desirable” traits while 
others do not. For some, the genetic 
conditions that PGD can now detect, 
Preimplantation Genetic Diagnosis
“I believe that when it comes to 
the application of  a genetic test 
in the embryo selection arena, 
that widespread use of  that for 
sex selection is a boundary that 
we should not cross  I think that 
is stretching to the breaking 
point the reasons why we are in 
the genetic technology business 
in the fi rst place.” 
Francis Collins, National 
Human Genome Research 
Institute
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such as hereditary deafness, are 
merely human variations that do not 
prevent an individual from leading 
a useful and satisfying life.  Some 
say that the use of PGD could make 
society less tolerant of people with 
disabilities.  Specifi c concerns have 
also been raised about using PGD 
for sex selection, given the history of 
discrimination against women and 
preference for male children that 
has existed — and continues to exist 
— in some cultures.
Finally, some worry that PGD will 
alter parental expectations of those 
children who have been carefully 
selected to possess certain attributes 
and cause tension between siblings 
who are the result of PGD and those 
who are not.
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Th e technology for genetic testing 
is changing rapidly in all areas, 
including reproductive genetic 
testing.  As was noted previously, 
new technologies such as gene chips, 
or “microarrays”, could soon allow 
individuals to learn about numerous 
gene mutations or variants by 
ordering a single test.  Th e advent 
of testing that can quickly reveal an 
abundance of genetic information 
— from the conclusive to the murky, 
from the serious to the trivial — will 
amplify the promise and pitfalls that 
now exist with genetic testing. 
Some argue that the more we 
know about our genetic makeup 
and that of our children, the better 
we and our doctors can manage our 
family’s health. However, not all 
genetic information may be equally 
informative, desirable or benefi cial.   
Helping patients make choices 
about testing will present new 
challenges for health care providers 
and genetic counselors. Providers 
may feel pressure to seek as much 
information as genetic testing 
can provide — more than the 
patient wants or needs. Economic 
effi  ciencies may drive the decision 
by commercial laboratories to test 
for everything at once, even if the 
patient and provider are interested in 
only a small subset of the test results. 
As more tests become available, 
patients may have to pay a premium 
for a test that is more accurate and 
reveals more information, which 
could have an eff ect on who has 
access to the best care. Insurance 
companies usually take a cautious 
approach in considering whether to 
cover new, cutting-edge technologies 
and their coverage policies could 
limit  the dissemination of new tests. 
Furthermore, as new testing 
comes on the market, it is not clear 
who will set the standards that will 
be used to gauge their accuracy or 
establish the guidelines for proper 
use and interpretation of the results. 
Such standards and guidelines 
already are lacking for much of what 
is currently available.  
Genetic counseling as a fi eld also 
will be challenged to keep pace with 
the ramifi cations of the technological 
changes. And health care providers 
likely will struggle to provide high 
quality care especially as a greater 
amount of time is needed to help 
each patient sift  through the growing 
list of testing options.  
Testing Before Pregnancy
Th e number of carrier tests 
available and the number of people 
off ered these tests will grow.  Some 
speculate that carrier testing will 
increase to a point where tests 
will be available for all recessive 
genetic disorders that cause serious 
childhood disease or death.  Others 
believe this use is not cost eff ective 
or appropriate and is unlikely to 
occur.  
As testing becomes part of adult 
medicine, there is the prospect 
that people will know a great deal 
about their own genetic makeup 
as young adults and will come to 
marriage and childbearing with that 
knowledge.  Of particular relevance 
will be the increase in predictive 
or predisposition testing.  A test 
undertaken to inform an adult 
about risk of cancer, diabetes or 
heart disease and perhaps to guide 
preventive care will also mean that 
parents will know that any child they 
have may inherit these same risks.    
 
Prenatal Genetic Testing
Th ere are a number of trends in 
prenatal screening and diagnostic 
genetic tests, all of which suggest 
that the prevalence of these tests and 
procedures will grow considerably in 
the years to come.  
Developments like fi rst-trimester 
maternal serum and nuchal fold 
translucency screening  allow 
earlier non-invasive screening tests.  
Many more prospective parents 
are likely to avail themselves of the 
information — and reassurance — to 
be gained from prenatal screening 
if the procedure carries no risk 
to the pregnancy and can occur 
weeks before anyone need know the 
woman is pregnant.  In addition, 
while the overall risks to women of 
death from induced abortion are 
low, the risk increases signifi cantly 
as pregnancy progresses, thus early 
The Future of Reproductive Genetic Testing
“We may be facing a paradigm 
shift, in that in the future 
there will be a vast distinction 
between well-planned and 
medically calibrated children 
and the accidental children of  
the poor.” 
Amy Laura Hall, Duke Divinity 
School 
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screening can protect the lives of 
women who subsequently choose 
termination based on the test results.
New techniques are being 
developed to collect fetal cells or 
DNA samples through non-invasive 
procedures to minimize the risk 
to fetus and mother.  Studies are 
underway to determine how to best 
obtain and concentrate fetal cells or 
free DNA that normally circulate in 
maternal blood during pregnancy 
so that chromosome, biochemical 
and DNA analyses can be performed 
using those cells. 
 
Th e recommendations for who 
should be off ered amniocentesis and 
CVS are also changing. Screening 
tests are off ered to many patients, 
but current guidelines dictate that 
diagnostic tests — tests that pinpoint 
the actual genetic mutation or 
chromosome abnormality — be 
reserved for those who have specifi c 
risk factors.  However, some studies 
have challenged this standard and 
suggest that diagnostic prenatal 
genetic testing may be off ered 
diff erently in the future.  Th ere is a 
developing recognition that some 
women without known risk factors 
may nevertheless want to pursue 
amniocentesis and CVS.  Because 
patients have varying tolerances for 
risk, some women might prefer to 
accept the small risk of miscarrying 
a healthy fetus in order to avoid 
even a remote risk of having a child 
with a genetic disease. Others, who 
may know they are high risk, may 
nevertheless choose to forgo testing 
altogether for fear of losing a wanted 
pregnancy. Recent studies in the 
Lancet and Genetic Testing, among 
others, have suggested that it may be 
preferable and cost-eff ective for all or 
nearly all prospective parents to be 
off ered prenatal diagnostic genetic 
testing and permitted to make the 
decision for themselves.
Th ere are those who argue 
that testing for more diseases 
in a broader patient population 
will greatly increase the overall 
number of pregnancy terminations. 
Furthermore, they worry that 
more and more genetic variations 
will come to be considered serious 
defects for which termination is 
sought. Th e future promises prenatal 
genetic testing characterized by more 




Any genetic test that can be used 
to test an adult may also be used to 
test an embryo.  Th ere are no limits 
to the types of genetic tests that may 
be performed on an embryo.  Th us, 
in the future PGD may be used 
to test an embryo for any genetic 
disease-causing mutation or trait 
that may be identifi ed. And as more 
couples use PGD as an add-on to 
IVF, PGD could allow parents to 
choose among embryos based on 
a range of genetic characteristics.  
PGD has already been used to detect 
— and select embryos free from — a 
mutation associated with a high risk 
of developing Alzheimer disease 
as an adult.  In the future, parents 
may use PGD to attempt to have 
children free of genetic risk factors 
for heart disease or any disease with 
a known genetic component.   And 
if it becomes possible to test for a 
gene associated with intelligence, 
height, athleticism or other “traits,” 
PGD could be used for that purpose 
as well.
Bundles, Panels and Chips
Uncertainties abound about how 
tests should be bundled and how 
much control patients will have 
over the information they receive.  
For example, in the future standard 
prenatal genetic testing could 
conceivably test for every known 
disease-causing mutation.  As an 
alternative, the number of tests could 
be limited but it is not at all clear 
how the limits should be drawn.  
Another possibility would be to 
allow prospective parents to opt-out 
of certain diagnostics; for example, 
if the “bundle” includes testing for 
susceptibility to adult-onset diseases 
such as Huntington or Alzheimer 
diseases but that information is 
not wanted, they could decline that 
information. 
“After all, if  parents are going 
through the trouble to have 
in vitro fertilization and 
then preimplantation genetic 
diagnosis to make sure the 
child is healthy, it’s but a short 
step for them to say, ‘well, why 
shouldn’t we get the best of  
all possible babies out of  this 
process?’ Assuming that they 
have some idea of  what that 
best will be.” 
Leon Kass, American Enterprise 
Institute
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Some disease-causing mutations 
will be present at varying frequencies 
in diff erent populations.  In the case 
of CF, this has resulted in test panels 
for the most prevalent mutations.   
In the case of sickle cell disease and 
Tay Sachs, screening programs have 
targeted particular populations. 
While limited panels and targeted 
screening are cost eff ective with 
today’s technologies and health 
care delivery systems, this approach 
also may mean that tests may not 
be developed for mutations that 
cause signifi cant disease in small 
population groups, particularly 
those groups with less economic 
power.  In addition, testing may 
not be made available to lower risk 
populations.  For example, as a result 
of the Tay Sachs screening programs 
predominantly in the Jewish 
community, the number of Tay 
Sachs births is now actually higher 
among non-Jews than among Jews 
(although still very rare). Looking 
to the future it is possible that high 
throughput testing platforms such 
as gene chips will bring costs down 
such that universal testing, even for 
rare mutations, can be off ered.   
The Future of Reproductive Genetic Testing
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Government Oversight of 
Reproductive Genetic Tests
Federal
Th e federal government does 
not typically directly regulate the 
practice of medicine, leaving such 
oversight to the states.  Th e federal 
government does, however, have 
authority to regulate certain aspects 
of genetic testing. As discussed in 
detail below, some federal agencies 
exert limited oversight of genetic 
tests and the facilities that perform 
them. 
Some have argued that 
government oversight of genetic 
testing has fallen between several 
regulatory cracks and that 
government involvement in this 
area is inadequate given the growing 
importance of genetic testing in 
medical care and in reproduction. 
But before any new regulatory 
actions are considered, it is 
important to understand the existing 
authorities that are now in play. 
   
FDA
Th e Food and Drug 
Administration (FDA) has limited 
regulatory authority over some 
aspects of genetic testing.  FDA 
regulates diagnostic test kits, such 
as those used to diagnose HIV or 
to detect pregnancy, as “in vitro 
diagnostic devices” (IVDs).  A small 
number of genetic tests are sold as 
freestanding “kits” or IVDs.  IVDs 
are subject to premarket approval or 
clearance requirements, which may 
require the submission of clinical 
data showing the device is safe and 
eff ective.   
FDA has approved a few 
molecular genetic tests for marketing 
as IVDs. One, approved in 2001, is 
a test for the overexpression of the 
HER2 gene in breast cancer patients.  
Th e other two tests, approved in 
2003, detect Factor V Leiden and 
Factor II, genetic abnormalities 
which are linked to blood clotting 
disorders. None of these FDA-
regulated tests are used, at least 
currently, in reproductive genetic 
testing. Moreover, considering that 
genetic tests for over 700 diseases are 
available clinically, those approved 
by FDA represent a negligible 
fraction of genetic tests. 
However, most genetic tests 
are not regulated as IVDs because 
they are not sold as kits. Rather, a 
laboratory off ers them as a medical 
service.  Th ese tests, developed 
in-house by a laboratory, are called 
“home-brew” tests. Because these 
tests are not sold as products, FDA 
does not regulate them or the clinical 
laboratories that use them. 
FDA does, however, regulate 
certain components used in 
developing home-brew genetic 
tests. FDA regulates “analyte 
specifi c reagents” (ASRs), the active 
ingredients of home-brew tests.  Like 
other medical devices, FDA classifi es 
ASRs according to their level of risk.  
Class I is the lowest risk and Class III 
the highest. FDA has the authority to 
impose additional requirements to 
assure the safety and eff ectiveness of 
Class II or Class III ASRs. However, 
FDA has classifi ed ASRs for genetic 
testing as Class I ASRs and thus 
they are not subject to heightened 
regulation. 
Two recent FDA actions suggest 
the agency may be laying the 
groundwork for more extensive 
regulation of new gene chip-based 
genetic tests as medical devices.  
In April 2003 FDA prepared a 
“draft  guidance” to help companies 
understand what they will need to 
submit to the agency in order to get 
the approval required to make the 
tests commercially available.  FDA 
noted that its goal was “to establish 
a set of recommendations that will 
both defi ne the levels of data needed 
to establish a reasonable assurance of 
safety and eff ectiveness of a device, 
and suggest the least burdensome 
path to market for manufacturers of 
multiplex and array devices.”  Also in 
2003, FDA notifi ed the manufacturer 
of a gene array chip that it could 
not sell the chip for diagnostic use 
without additional agency review 
and that the chip could not be 
classifi ed as an ASR.  However, it is 
not clear what degree of review FDA 
intends to apply to this technology 
and what the specifi c requirements 
will be.
With regard to PGD, FDA 
involvement to date has been 
limited.  FDA generally has 
not sought to regulate assisted 
reproduction directly, although it 
does regulate the drugs and devices 
used as a part of fertility treatments. 
FDA also regulates human tissues, 
including reproductive tissue, 
used for transplantation, but such 
oversight is limited to preventing 
disease transmission and ensuring 
tissue integrity by requiring 
procedures for tissue testing, storage, 
and record keeping.  FDA does 
not generally review the safety and 
eff ectiveness of fertility treatments, 
such as PGD, that use reproductive 
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tissue; it is unclear whether FDA has 
the authority to do so.  It is possible 
that FDA could seek to regulate 
the embryo resulting from IVF and 
PGD as a “biological product,” and 
require premarket approval on that 
basis, but there has been no serious 
consideration of such an approach to 
date.  While FDA has at times been 
willing to extend existing authority 
to cover new technologies, these 
decisions are generally made because 
of a perception that the technologies 
at issue pose serious public health 
threats.  For example, in 2001, FDA 
asserted authority over ooplasm 
transfer, an experimental fertility 
procedure, stating that it could be 
performed only as part of an FDA-
authorized research protocol.
Even if FDA were to attempt to 
increase regulation of genetic testing 
including reproductive genetic 
testing, there are still limits on its 
authority that could aff ect its ability 
to dictate safeguards for patients. 
Although FDA regulates the claims 
a manufacturer may make about 
an approved product, it does not 
have authority to regulate how a 
doctor uses or administers it. Such 
decisions are considered part of 
medical practice.  An analogous 
situation is frequently seen with 
FDA-approved drugs. Th e drug may 
be approved for specifi c indications, 
but once approved, doctors are free 
to use their judgment to prescribe 
the drug for other conditions.  Th us, 
even if FDA found a way to require 
premarket approval for genetic tests, 
the agency could not restrict how 
health care providers decide to use 
the tests. Th e role of professional 
societies in establishing guidelines 
for how providers use tests and 
procedures will be discussed below.
CLIA
One of the key issues in the 
regulation of genetic testing is 
whether or not there is adequate 
oversight of the laboratories that 
perform the genetic analysis.   Most 
genetic testing is considered a 
commercial service that is provided 
through clinical laboratories and is 
subject to regulation by the Centers 
for Medicare and Medicaid Services 
(CMS) through a law known as the 
Clinical Laboratory Improvement 
Amendments of 1988 (CLIA).  
In enacting CLIA, Congress 
directed the Secretary of the 
Department of Health and Human 
Services (HHS) to issue standards 
for the certifi cation of laboratories 
in order “to assure that such 
laboratories will consistently 
perform tests in a valid and reliable 
manner.”  CMS is responsible for 
developing and enforcing these 
standards, which apply to all clinical 
laboratories regardless of whether 
or not they service Medicaid and 
Medicare benefi ciaries. 
CLIA defi nes a “clinical 
laboratory” as a laboratory that 
examines materials “derived from 
the human body” in order to provide 
“information for the diagnosis, 
prevention, or treatment of any 
disease or impairment of, or the 
assessment of the health of, human 
beings.”   CLIA requirements include 
laboratory personnel qualifi cations, 
documentation and validation of 
tests and procedures and quality 
control standards.  Th ese general 
requirements apply to laboratories 
performing genetic tests when the 
results of those tests are used as part 
of health care decision making. It is 
unclear whether so-called “research” 
laboratories that develop new genetic 
tests for rare genetic disorders are 
always CLIA certifi ed.  Physicians 
ordering genetic tests from these 
laboratories may not be aware that 
such laboratories are not permitted 
to report the results of their tests 
back to the patient or physician 
unless they are CLIA certifi ed.
Th e stringency of CLIA regulation 
depends on the complexity of the 
test that the laboratory performs.  
“High complexity” tests are generally 
grouped according to “specialty 
areas” and are subject to specifi ed 
additional requirements, including 
profi ciency testing requirements.  
Profi ciency testing is a means by 
which a laboratory demonstrates 
its ability to accurately perform 
certain tests. However, while 
genetic tests are considered high 
complexity, there is no specialty 
area for molecular genetic tests and 
no specifi ed profi ciency tests for 
them.  Laboratories must therefore 
determine for themselves how to 
demonstrate their profi ciency in 
performing most genetic testing. 
Some do so by using profi ciency 
testing programs established by 
professional organizations; however, 
use of these programs is not 
required under CLIA.  Cytogenetics 
(chromosome analysis), in contrast, 
is recognized as a specialty area and 
some cytogenetic-specifi c standards 
are required under CLIA.
Th e absence of a molecular 
genetic testing specialty area under 
CLIA, and in particular of uniform 
prescribed profi ciency testing 
requirements for genetic testing, 
makes it diffi  cult to evaluate the 
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accuracy of laboratory performance 
of genetic tests.
While laboratories performing 
prenatal and carrier testing fall under 
CLIA jurisdiction, its applicability 
to laboratories that perform genetic 
testing for PGD is less certain.  Th e 
outstanding question is whether 
the genetic tests performed in PGD 
laboratories provide information 
that will be used to diagnose, treat or 
prevent disease or to assess human 
health. Some within the agency 
worry that including PGD within 
the defi nition would require CMS 
to take the position that an embryo 
meets the legal defi nition of a 
human being.  It is unclear whether 
this concern is well-founded since 
neither the agency nor any court has 
had occasion to formally address 
it. Some PGD providers argue that 
their activities constitute the practice 
of medicine and are not within the 
scope of CLIA.
Even if CLIA reached all 
reproductive genetic testing, many 
observers believe that CLIA’s 
requirements are inadequate.  Th e 
relatively restricted scope of CLIA 
ultimately limits its power to deal 
with many of the issues raised 
by genetic testing. Th e focus of 
the statute is the environment in 
which tests are performed and the 
processes involved in performing 
them.  
In addition, although CLIA does 
address some aspects of analytic 
validity — whether the lab can 
perform the test accurately — it does 
not address clinical validity, i.e. the 
accuracy with which the test will 
predict a clinical outcome, or clinical 
utility, i.e. whether the test is useful 
for health and treatment decision 
making. Each laboratory director 
makes these determinations and 
decides whether to off er a genetic 
test, without any oversight from 
CLIA.  
CDC
Th e Centers for Disease 
Control and Prevention’s activities 
include monitoring, detection and 
surveillance of health and disease, as 
well as data collection and analysis.  
CDC diff ers from FDA and CMS 
in that it does not have specifi c 
statutory authority to regulate a 
particular industry (e.g., medical 
device manufacturers, clinical 
laboratories).  Nevertheless, CDC 
engages in activities related to some 
aspects of reproductive genetics. 
CDC advises CMS concerning 
the implementation of CLIA 
through the Clinical Laboratory 
Improvement Advisory Committee 
(CLIAC).  In 1997, CLIAC formed 
a Genetic Testing Working Group, 
whose purpose was to defi ne 
CLIA’s applicability and scope with 
respect to all phases of genetic 
testing.  CLIAC has made several 
recommendations concerning 
genetic testing, including the 
development of profi ciency testing 
standards for clinical laboratories 
engaged in molecular genetic 
testing.  In 2000, CDC announced its 
intention to revise CLIA regulations 
applicable to laboratories performing 
human genetic testing by creating 
a new specialty area that would 
address all phases of genetic testing.  
To date, no proposed regulations 
have been issued.
CLIAC also has made 
recommendations concerning 
regulation of laboratories engaged 
in in vitro fertilization.  In 1998, 
CLIAC recommended that 
embryo laboratory procedures be 
under the purview of CLIA.  Th is 
recommendation has not been 
adopted by CMS.
Th rough the Pregnancy Risk 
Assessment Monitoring System 
(PRAMS), CDC also collects data 
related to maternal attitudes and 
experiences prior to, during and 
immediately following pregnancy.   
Questions include whether a woman 
had health insurance coverage 
before and during pregnancy, when 
she began receiving prenatal care, 
whether she encountered diffi  culties 
in accessing prenatal care, the 
content of discussions between the 
pregnant woman and her health 
care provider and early infant 
development and health status. 
In the current PRAMS 
questionnaire (2004-2007), among 
more than 50 questions asked in 
every state, there is only one question 
related to reproductive genetic 
testing. One subpart of one question 
asks whether during a prenatal care 
analytic validity refers to the ability 
of a laboratory test to identify the 
targeted characteristic (e.g., a DNA 
sequence variant).
clinical validity refers to a test’s 
ability to predict a particular 
clinical outcome.
clinical utility  refers to a test’s 
ability to provide information 
that leads to an improved health 
outcome.
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visit, a health care provider discussed 
“doing tests to screen for birth 
defects or diseases that run in my 
family.”  No questions ask whether 
the woman actually used the tests. 
Th ere are additional questions that 
states may choose to add to the 
questionnaire administered in the 
state.  Among these questions are 
two on whether the mother used 
assisted reproductive technologies, 
although there is no mention of 
PGD. 
CDC implements the 1992 
Fertility Clinic Success Rate and 
Certifi cation Act (FCSRA). Th is law 
requires clinics that provide IVF 
services to report pregnancy rates 
annually to the federal government. 
Th e FCSRA requires clinics to 
report data concerning the type of 
assisted reproduction procedure 
used, the medical diagnosis leading 
to IVF treatment, the number of 
cycles of IVF attempted, whether 
fresh or frozen embryos were used, 
the number of embryos transferred 
in each cycle, the number of 
pregnancies achieved and the 
number of live births. Th e statute 
does not require clinics to report 
the health status of babies born as 
a result of the procedure or the use 
of diagnostic tests such as PGD.  
CDC analyzes the data and makes 
its fi ndings available to the public, 
including via the Internet. 
In 2001, the most recent year for 
which data are available, 384 clinics 
reported data.  Th e law requires 
CDC to list on its web site the names 
of clinics that do not report at all or 
that fail to verify the accuracy of the 
data. Th irty-seven clinics known to 
be in operation throughout 2001 that 
did not report data are listed as non-
reporters. Other than being listed 
by CDC, there are no penalties for 
failure to report. 
Federal Oversight of Research
Federal regulations require all 
institutions receiving federal funds 
to follow rules aimed at protecting 
human participants in medical 
research.    Requirements include 
review of research protocols by an 
institutional review board (IRB), 
informed consent of the research 
subject and periodic reporting 
obligations.  Special protections are 
in place for pregnant women and in 
utero fetuses in order to minimize 
the risk of harm. Research that will 
be used to support an application 
for approval of a product by FDA is 
also subject to these human subject 
protection regulations.
If a federally-funded research 
institution were to conduct research 
on reproductive genetic technologies 
with human participants, such 
research would be subject to these 
requirements.  In practice, however, 
some reproductive genetics research, 
and in particular research on 
PGD, is precluded from receiving 
federal funds.  Th is is because of a 
1996 Congressional ban on federal 
funding of any research in which 
an embryo is created, destroyed 
or subjected to more risk than is 
permitted for an in utero fetus.  As 
a result, embryo-related research is 
most oft en conducted with private 
funds.
Federal funding may, however, be 
used for research involving fetuses 
under certain circumstances.  Such 
research would be covered by the 
federal human subject protections.
In the absence of federal funding 
for research and FDA premarket 
review of genetic tests, research to 
develop these tests is not subject to 
federal human subject regulation.
Government Advisory 
Committees on Genetic Testing: 
Unheeded Advice
Several government advisory 
bodies have reviewed the oversight 
of genetic testing in the United 
States and made recommendations 
for improvement.  While these 
bodies did not consider reproductive 
genetics specifi cally, the concerns 
they identifi ed are relevant to the 
oversight of reproductive genetic 
testing. However, very few of their 
recommendations for enhanced 
oversight have been adopted. 
In 2001, President Bush 
established the President’s Council 
on Bioethics (PCB) to advise him 
on emerging bioethical issues.  
Although the PCB charter does not 
specifi cally refer to  reproductive 
genetic testing, the Council 
addressed several issues related to 
assisted reproduction, including 
PGD, in a March 2004 report, 
Reproduction and Responsibility: Th e 
Regulation of New Biotechnologies.  
Th e PCB’s recommendations 
included undertaking a federally 
funded study into the health and 
well-being outcomes of children 
born using assisted reproductive 
technologies including PGD, 
expanding the data collected by the 
FCSRA to include data about use of 
PGD, and Congressional prohibition 
of certain reproductive techniques 
such as the creation of animal-
human hybrid embryos. (Several of 
these topics will be discussed later in 
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Government Advisory Committee on Genetic Testing










Address concerns that: 
• genetic tests introduced 
clinically before safety, 
eff ectiveness and utility 
demonstrated; 
• clinical laboratories not 
meeting standards; 
• patients and 
providers lack suffi  cient 
information to 
understand the tests
• All genetic testing research should be 
approved by an IRB;
• Federal agencies should facilitate research 
into safety and eff ectiveness;
• Specifi ed data should be collected prior to 
commercial availability of test;
• Clinical validity should be established 
before commercial availability;
• CDC should implement profi ciency 
standards for laboratories conducting 
genetic tests as part of a national 
accreditation program for genetic testing 
laboratories. 
Report issued in 1997. None of 
the recommendations adopted.
Report led to establishment of 














Implement Task Force 
Recommendations. 
SACGT was 
asked to frame its 
recommendations 
around fi ve issues: 
• criteria that should be 
used to assess benefi ts 
and risks of genetic tests; 
• tailoring criteria to 
diff erent categories of 
tests; 
• process that should be 
used to collect, evaluate 
and disseminate data on 
tests in these categories; 
•options for oversight of 
genetic tests; 
• appropriate level 
of oversight for each 
category of test.
• Analytic and clinical validity, clinical 
utility, and social consequences should be 
major criteria used to assess benefi ts and 
risks of genetic tests; 
• Tests should be classifi ed into “scrutiny 
level.”  Review should be based on factors 
including use of test, type of mutation being 
detected, treatment availability, potential 
for stigma based on test results and ease of 
interpretation of results;
• FDA should be responsible for review, 
approval and labeling of all new genetic 
tests,.
• CLIA regulations should be augmented to 
ensure quality of laboratories conducting 
genetic tests; 
• IRB review should be conducted of all 
research protocols for genetic tests in which 
individually identifi able human subjects or 
samples used; 
• Tests already on market should be 
reviewed for clinical effi  cacy by a 
multidisciplinary group, which should 
develop guidelines for their appropriate use.
Report issued in 2000.
In 2001, then Secretary Donna 
Shalala stated that HHS would 
implement the committee’s 
recommendations.  
Th ereaft er, committee retracted 
its proposed criteria for 
determining level of scrutiny, 
stating that,  “in the fi nal 
analysis, SACGT came to 
question the feasibility and 
utility of such a methodology.”  
SACGT’s charter expired 
in 2002.  None of its 










Serve as a public forum 
for deliberations on 
broad range of human 
health and societal 
issues raised by genetic 
technologies and advise 
the Secretary on these 
issues.
• Sent letters to Secretary of HHS in support 
of genetic discrimination legislation.
Has heard testimony and 
engaged in discussion on 
health care professional 
education, reimbursement for 
genetic technologies, genetic 
discrimination and direct-to-
consumer marketing of genetic 
testing.
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this report). Th us far, no actions have 
been taken by the Administration 
or Congress to respond to these 
recommendations.
States
States traditionally have had 
primary authority to pass laws and 
develop regulations protecting the 
health, safety and welfare of their 
citizens.  States fulfi ll this oversight 
role in a variety of ways. 
States license physicians and other 
healthcare providers.  However, they 
do not license physicians to perform 
specifi c procedures or impose  
specifi c limits on their  practice.  
Rather, board certifi cation by various 
specialty organizations defi nes 
competence to practice a specialty or 
subspecialty, although there are few 
regulations prohibiting physicians 
from practicing outside their area of 
specialty.
Th ere are a variety of other 
health professionals relevant 
to reproductive genetic testing, 
including nurses and genetic 
counselors.  Nurses are licensed by 
state licensing boards. Only a few 
states license genetic counselors, who 
are certifi ed by the American Board 
of Genetic Counseling.
Some states regulate medical 
laboratories, including placing 
limits on who may order a test 
from a laboratory.  Some states 
categorically prohibit direct patient 
access to clinical laboratory testing, 
while others allow some clinical 
laboratory tests such as cholesterol 
or pregnancy tests to be ordered 
by patients without a prescription 
from a health care provider.  And 
still other state laws are silent on the 
issue, which leaves the determination 
of whether to off er direct access 
testing up to individual laboratories. 
While there has been an increasing 
trend toward direct marketing of 
some genetic tests over the Internet, 
it appears that most genetic testing in 
the reproductive context is obtained 
through medical professionals. Th is 
is particularly true in the case of 
PGD and prenatal testing, because 
the skills of a health care professional 
are required to obtain the DNA 
sample needed for testing.  However, 
direct testing may be more feasible 
in the area of carrier testing, since 
an individual can easily provide 
a sample of his or her own tissue 
— usually a simple blood test — to a 
laboratory.
For the most part, state agencies 
implement the CLIA program but 
do not add to it, although some 
states have enacted more stringent 
requirements.  New York and 
Washington states are exempt from 
CLIA because their own regulatory 
framework has been deemed by the 
federal government to be suffi  ciently 
rigorous. Most states have not 
included laboratories that conduct 
IVF or PGD in their laboratory 
oversight duties. However, New 
York’s standards for laboratories do 
include oversight of the genetic tests 
associated with PGD by the state 
Department of Health.  Laboratories 
must demonstrate their ability to 
detect in an embryo each mutation 
for which they off er testing.
Under the FCSRA, CDC 
developed a model state program 
for certifying laboratories that work 
with human embryos. It includes 
standards for procedures, record 
keeping and laboratory personnel 
and criteria for inspection and 
certifi cation. According to CDC, no 
state has formally adopted the model 
program.
States have jurisdiction over 
insurance benefi ts included in health 
insurance plans sold within their 
borders.  Some states mandate that 
providers off er prenatal testing.  For 
example, a law in Washington state 
requires that insurers providing 
pregnancy or childbirth benefi ts 
must also include benefi ts covering 
tests and procedures relating to 
genetic diagnosis of the fetus. 
Washington also requires health care 
providers to inform pregnant women 
about the availability of prenatal 
tests.  A state-administered program 
in California requires providers to 
off er serum screening blood tests to 
all women who begin prenatal care 
before the 20th week of pregnancy. 
Testing is subsidized and insurance 
companies are required to pay for the 
test. Subsidized follow-up services, 
including genetic counseling, 
ultrasound and amniocentesis, are 
available at state-approved Prenatal 
Diagnosis Centers. 
Fift een states have enacted laws 
mandating that insurers off er or 
provide some degree of coverage for 
infertility treatments, which may or 
may not include IVF services, but 
no state currently requires insurance 
coverage for genetic testing of 
embryos.
A state’s ability to infl uence health 
care policy by mandating certain 
types of insurance coverage is limited 
by a federal law (the Employee 
Retirement Income Security Act or 
ERISA) that exempts employers who 
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assume the risk for their employees’ 
health care costs from state 
insurance mandates. Th e practical 
eff ect is that nationwide about half of 
the 131 million Americans who get 
health insurance through their jobs 
may not be receiving the benefi ts 
required by state laws.
Some states have used their 
authority over medical practices 
to pass laws related to assisted 
reproductive technology (ART). 
Th ese laws are mainly concerned 
with defi ning parentage, ensuring 
that the transfer or donation of 
embryos is done with informed 
consent or ensuring insurance 
coverage for fertility treatment. Some 
states prohibit the use of embryos 
for research purposes and one state, 
Louisiana, prohibits the intentional 
destruction of embryos created 
via IVF. For the most part though, 
states have not assumed oversight 
responsibilities for fertility clinics. 
Self-Regulation and the Role of 
Professional Organizations
Medical and scientifi c 
professional organizations are a 
source of oversight of reproductive 
genetic testing. Th ese groups, which 
generally comprise members of a 
particular occupation or specialty, 
serve a variety of oversight or 
self-regulation functions. Th ey 
educate members about advances 
in the fi eld and develop guidelines 
addressing appropriate conduct or 
practices such as indications for 
particular treatments.  Th ey may  
require compliance as a condition of 
membership.  Professional guidelines 
and standards vary widely in their 
scope and level of specifi city.  In the 
case of genetic testing, guidelines 
may describe the indications for a 
particular test, give specifi c technical 
instructions for how the laboratory 
should perform the test or provide 
information on how providers 
should interpret results. 
For the most part, professional 
guidelines and standards 
are voluntary.  Professional 
organizations typically do not 
have authority to sanction 
members for noncompliance. 
Unless the organization is 
specifi cally authorized to act on the 
government’s behalf in administering 
and enforcing government 
standards, actions of the professional 
organization do not have the force 
of law.  
Th erefore, professional guidelines 
oft en play an exhortative role, setting 
a standard for the best possible 
conduct by providers.  Th ey also may 
have a legal impact.  Courts may use 
clinical practice guidelines to help 
determine whether a provider met 
the “standard of care” in treating a 
patient.  Th e standard of care is the 
minimum level of non-negligent 
healthcare that a provider must 
give, and is generally defi ned as 
reasonable and customary treatment 
provided by a competent medical 
practitioner. If guidelines are used 
as evidence of the standard of care 
by a court, then a provider who 
deviates from them could face 
liability if a patient is harmed as a 
result.  Conversely, guidelines may 
also function as a ‘safe-harbor’ for 
medical practitioners who would 
not be liable for any claims arising 
from treatment in compliance with 
guidelines. 
However, courts diff er regarding 
the evidentiary value of guidelines 
in establishing the standard of care.  
Courts generally weigh heavily 
the quality of the guideline and 
its general acceptance within the 
relevant medical specialty. Some 
guidelines are not comprehensive, do 
not represent professional consensus, 
are supported by poor research and 
data or were promulgated by an 
entity with a potential confl ict of 
interest, such as an insurer or HMO. 
Such guidelines are less likely to be 
persuasive to a court determining 
the standard of care.   In contrast, 
guidelines supported by evidence 
and refl ecting consensus within 
the medical community are more 
likely to be persuasive to a court. 
While disseminating guidelines 
and persuading providers to adhere 
to them is oft en challenging, their 
potential legal impact can create a 
strong impetus for their adoption.  
Some observers have raised the 
concern that guidelines refl ect not 
how the practice of medicine should 
be performed but how it is already 
done.  Oft en guidelines are not 
developed until a test or procedure 
is already commonplace, when 
practice patterns have already been 
established.  Th is may refl ect the 
many challenges of creating new 
guidelines as well as the reluctance of 
the profession to develop guidelines 
with incomplete information about a 
new test or procedure.  
Professional societies such as 
ACOG and ACMG have each 
published guidelines regarding 
carrier and/or prenatal genetic 
testing.  But the guidelines that exist 
cover only a fraction of the genetic 
tests that can be performed. 
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ACOG publishes both 
professional guidelines and opinions. 
ACOG has addressed specifi c tests 
such as Tay Sachs, Canavan disease 
and cystic fi brosis, and ethical 
issues such as sex selection and 
embryo research.  Th ere are also 
a few Practice Bulletins on topics 
related to reproductive genetics 
such as Prenatal Diagnosis of Fetal 
Chromosomal Abnormalities.  
Overall, the intent of all of these 
documents is to be educational 
rather than directive.  Following the 
standards is voluntary. ACOG has 
avoided regarding these statements 
as defi ning the standard of care, 
although these documents may be 
viewed as performing that function.
Th e American College of Medical 
Genetics has also issued policy 
statements and guidelines for some 
areas of carrier and prenatal genetic 
testing. ACMG has developed 
guidelines for carrier testing for 
cystic fi brosis and Canavan disease, 
and prenatal testing for open 
neural-tube defects.  ACMG also has 
published more general statements 
on genetic testing for a specifi c 
disease such as Huntington disease, 
that also include discussion of 
prenatal testing.  
In 2001, the American Society 
for Reproductive Medicine (ASRM) 
issued a practice committee opinion 
addressing PGD, stating that PGD 
“appears to be a viable alternative 
to post-conception diagnosis and 
pregnancy termination.”  It further 
states that while it is important 
for patients be aware of “potential 
diagnostic errors and the possibility 
of currently unknown long-term 
consequences on the fetus” from the 
biopsy procedure, “PGD should be 
regarded as an established technique 
with specifi c and expanding 
applications for standard clinical 
practice.”  ASRM also has issued an 
ethics committee opinion cautioning 
against the use of PGD for sex 
selection in the absence of a serious 
sex-linked disease.  However, there 
are ASRM members who off er and 
advertise sex selection services for 
non-disease related reasons such as 
“family balancing.”
Th e PGD International Society 
(PGDIS), was created in 2002 to 
promote PGD and to organize and 
coordinate research, education and 
training in PGD among providers 
working in the fi eld.  In 2004, PGDIS 
developed and published Guidelines 
for Good Practice In PGD outlining 
topics such as setting up a PGD 
program, patient management, 
IVF and PGD protocols, diagnostic 
techniques, embryo transfer, spare 
embryos, follow-up of pregnancy 
and quality control and assurance.  
Th e European Society for Human 
Reproduction and Embryology 
(ESHRE) tracks PGD outcomes 
on a voluntary basis, but captures 
primarily European data. In May 
2004, ESHRE’s PGD consortium 
released “Best Practice Guidelines” 
for PGD testing.  ESHRE’s guidelines 
are currently under review by 
ESHRE membership. 
It is interesting to note that the 
ESHRE guidelines begin with an 
explanation of why guidelines are 
important.   According to ESHRE, 
genetic testing of embryos for single-
gene disorders (referred to as PGD) 
and to  screen for chromosomal 
abnormalities (referred to as PGS)  
“are treatment options that are 
relatively unregulated and lack 
standardization compared to other 
diagnostic testing.” According 
to the guidelines, this is “ironic 
considering the comparative 
diffi  culty in achieving the highest 
levels of accuracy and reliability 
with single cells as part of PGD/PGS 
versus more routine genetic testing.”  
Th ey recommend that one step 
towards higher quality overall and 
standardization for PGD is to “build 
consensus opinion on best practices 
within the PGD/PGS community.”
Th e College of American 
Pathologists (CAP) runs voluntary 
programs certifying clinical 
laboratories including those 
performing genetic testing.  In 
conjunction with ACMG, CAP 
operates profi ciency testing 
programs for a variety of genetic 
testing, including the molecular 
genetics and cytogenetics that are 
part of carrier and prenatal testing.  
CAP also has programs in some 
areas specifi c to reproductive genetic 
testing, such as maternal serum 
screening and prenatal genetic 
testing.  Th ey also certify laboratories 
in embryology, including the 
techniques and procedures necessary 
for IVF, although the certifi cation 
does not include standards for 
PGD.   In addition, CAP has 
been empowered by the federal 
government to inspect laboratories 
seeking certifi cation under CLIA.
Oversight by Court Action
Courts play an important role in 
overseeing health care, including 
reproductive genetic testing. Th e 
possibility of malpractice liability 
provides a strong incentive for health 
care providers to conform to the 
Reproductive Genetic Testing: Issues and Options for Policymakers 39
standard of care, which may require 
adopting new medical technologies.  
Lawsuits claiming medical 
malpractice following the birth 
of a child with an abnormality 
preceded the advent of reproductive 
genetic testing, and gave rise to 
legal theories, such as “wrongful 
birth” and “wrongful life,” that are 
potentially applicable to the genetic 
testing context. For example, a parent 
who gives birth to a child with a 
genetic abnormality and either was 
not off ered a genetic test or believes 
the test was improperly interpreted 
may sue the provider who failed to 
order or properly interpret a test 
or the laboratory that improperly 
performed a test or incorrectly 
reported the results.  Th e parent may 
allege that, but for the provider’s 
negligent actions, the parent would 
not have chosen to become pregnant 
or continue a pregnancy.  Th ese cases 
have been called “wrongful birth” 
suits. Th e parent may also argue on 
behalf of the child that, but for the 
provider’s negligent action or failure 
to act, the child would not be alive—
so called “wrongful life” suits. Courts 
diff er on the extent to which they 
recognize these arguments or would 
permit damages to be awarded. 
Th ese legal theories have, in a 
few cases, been applied to PGD. 
In one case, the parents of a child 
born with cystic fi brosis following 
PGD, as well as the child, sued those 
involved with the embryo screening 
for failing to detect the condition. 
Th e parents made the claim of “loss 
of consortium,” meaning the loss 
of the companionship they would 
otherwise have had with a child not 
aff ected by cystic fi brosis. Th e court 
rejected this claim, fi nding that it was 
too speculative. Also, it ruled that the 
defendants could not be held legally 
responsible for causing the child to 
suff er from a genetic disease.   
Th e child made the claim of 
“wrongful life,” alleging that the 
defendants’ negligent failure to detect 
cystic fi brosis denied his parents 
an opportunity not to give birth to 
him. Th e court rejected this claim 
as well.  Indeed, most courts have 
rejected wrongful life claims in other 
circumstances, such as those arising 
from a fl awed prenatal test, in part 
because doing so would require 
accepting the general argument that 
there can be instances in which an 
impaired life is worse than no life at 
all.   
Th e proliferation of genetic testing 
and the ability to perform increasing 
numbers of tests prior to birth is 
likely to create more opportunities 
for such cases to be brought. For 
example, if a provider performs 
carrier testing on a prospective 
parent and learns that the parent 
is a carrier at heightened risk for 
passing on a particular disease, what 
obligation, if any, does the provider 
have to disclose this information to 
other family members potentially 
at risk — including any subsequent 
children? While there have been a 
few court cases addressing this issue, 
court rulings have been inconsistent, 
leaving providers without clear 
guidance on how to proceed. 
In determining a provider’s 
responsibility and liability for a bad 
outcome, the court asks whether the 
provider followed the standard of 
care.  Answering this question may, 
in turn, be informed by whether 
specifi c practice guidelines or 
recommendations from a relevant 
professional society exist and are 
generally followed by others in the 
provider’s specialty.
“In the case where a mother 
might terminate a pregnancy 
based on a mutation, one has 
to be very sure that one knows 
that mutation correlates to that 
disease.”              
Sharon Terry, Genetic Alliance
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Reproductive genetic testing 
provides tremendous benefi ts 
to prospective parents seeking 
information about their risk for 
having a child with a genetic 
disease.  Yet for many observers 
these tests raise questions about 
whether there is suffi  cient oversight 
of these technologies.  Some ask 
whether clear oversight rules are 
needed to ensure the ethical use of 
reproductive genetic testing.  Others 
focus on how to improve clinical 
delivery of tests to patients, ensuring 
that the right test is off ered to the 
right person at the right time.  Many 
want increased oversight of the 
accuracy and safety of reproductive 
genetic tests.  And some ask 
about access, whether the cost of 
reproductive genetic testing means it 
will be available only to a privileged 
few. 
Th ere are a variety of intelligent 
public policy approaches that could 
address these concerns.  In this 
section we suggest an array of policy 
options to respond to diff erent  
points of view.  Each option 
also includes arguments for and 
against, exploring the strengths and 
weaknesses in each approach.
Ethical Use of Reproductive 
Genetic Testing
Concerns about the ethical use 
of reproductive genetic testing take 
a variety of forms.  Some observers 
emphasize that the growth of 
reproductive genetic testing over 
time will mean the destruction of 
many more embryos and fetuses and 
a decrease in the value placed on 
human life.  Th ese concerns are most 
oft en raised about prenatal testing 
or PGD. Fewer concerns have been 
raised about the use of carrier testing 
before pregnancy because such tests 
can inform decision making before 
conception and thus do not directly 
result in the discarding of embryos 
or termination of pregnancy. 
Many concerns relate to why 
testing is used, whether parents 
are attempting to prevent a life-
threatening disease or whether they 
are pursuing testing for a disorder 
that is amenable to treatment or 
an inherited characteristic with no 
health impact.  Of course, most 
people acknowledge that the line 
between these two kinds of use is 
sometimes diffi  cult to draw.
Advances in testing technology 
will soon make it possible — and 
perhaps more tempting — for 
parents to test for many things 
at once and to go beyond the 
conditions that now are the focus of 
prenatal genetic tests.  For example, 
an add-on to amniocentesis or CVS 
for maternal age might be to test 
for genetic predisposition to adult-
onset diseases.  Some are troubled by 
the impact of such decisions on the 
relationships between parents and 
children.
Some who have concerns about 
the ethics of reproductive genetic 
testing would like to see targeted 
restrictions to moderate the impact 
on individuals, families and society. 
Others would ideally want prenatal 
testing and PGD banned completely, 
although most acknowledge that it 
would be diffi  cult to accomplish this. 
A variety of approaches to limit the 
uses of reproductive genetic testing 
and/or the impact of these tests 
follows.
Policy Options
“These are not decisions that 
should be made by some 
political elite; they are not 
decisions that should be made 
by religious elite.  These are 
decisions that we all have a 
stake in because we all share a 
common heredity.” 
C. Ben Mitchell, Trinity 
Evangelical Divinity School  
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GOVERNMENTAL  Ethical Use
Option: Establish federal or 
state rules for ethical uses of 
reproductive genetic testing.
Current oversight of reproductive genetic testing 
is highly fragmented, but where it does occur it 
is aimed primarily at accuracy and safety issues.  
Government could also play a role by setting 
ethical limits on the uses of reproductive genetic 
testing.
Congress, federal agencies or state governments 
could create and enforce prohibitions of 
prenatal testing or PGD for uses determined to 
be unacceptable (e.g. sex selection for reasons 
not related to health).  Federal or state agencies 
could also license and inspect facilities that 
perform or process reproductive genetic testing 
to ensure compliance with prohibitions.
Government bodies could also collect data on 
which tests are performed and how information 
is used for reproductive decision making to help 
inform policymaking. 
In addition to setting and enforcing limits and 
collecting data, government could play a more 
signifi cant role in overseeing the accuracy and 
safety of reproductive genetic testing.
Arguments for:
• Clear government-mandated restrictions 
will create certainty about what is and is not 
permissible, providing legally enforceable 
rules based on shared societal values.
• The process of creating federal or state rules 
will stimulate a productive public discussion 
about how to effectively oversee genetic 
testing and what limits are appropriate.
• Limits on the use of testing will result 
in fewer abortions of fetuses and fewer 
embryos discarded or destroyed on genetic 
grounds.  
Arguments against: 
• This approach constitutes a signifi cant 
intrusion into private medical practice. 
These decisions are best left to patients and 
providers.
• Any limits on decision making in human 
reproduction raises concerns about 
reproductive choice and could be subject to a 
Constitutional challenge.
• There is no societal consensus on appropriate 
uses. It will be diffi cult for any entity to draw 
lines between acceptable and unacceptable 
uses.
• Enforcement of such policies requires 
devising systems to determine why testing, or 
subsequent abortion, was performed.
• Setting limits nevertheless gives explicit 
government approval to practices that many 
people reject outright.
• Increased oversight will affect ease of access.  
In general, more scrutiny will mean restricted 
or delayed availability and increased costs. 
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GOVERNMENTAL   Ethical Use
Option: Federal or state ban of PGD.
Unlike carrier testing and prenatal testing, PGD 
is not a common part of reproductive health 
care.  Already banned or restricted in some 
countries, PGD is the form of reproductive genetic 
testing most likely to be targeted for a ban.  PGD 
requires the creation and sometimes leads to 
the destruction of embryos.  Some who believe a 
human embryo has the moral status of a live born 
child believe that PGD should be banned because 
of the loss of embryos involved. 
There are others who do not hold such a fi rm 
position on the moral status of the early human 
embryo but who nonetheless oppose PGD because 
they view it as unnatural and as violating the 
natural process of procreation. Also, some argue 
that PGD should be avoided even if it is not 
inherently wrong or offensive because it places 
society atop a slippery slope that will lead to 
genetic enhancement and human control of 
evolution.
Congress or state legislatures could decide that 
PGD is suffi ciently problematic to justify banning 
the procedure entirely.
Arguments for:
• Any use of PGD is unacceptable because it 
results in human embryos being destroyed.
• Any use of PGD, no matter how sympathetic the 
reason, is an unwarranted intrusion into the 
natural process of procreation. 
• PGD should be banned because it is 
discriminatory and is a form of eugenics. 
• New technologies should not be allowed 
without limits. PGD should be banned, at 
least until its implications are more clearly 
understood.
• A ban will contribute to the common good.  
• A ban provides a bright-line rule and clarity 
about what is and is not permitted.  
Arguments against: 
• This approach is too blunt an instrument 
because it does not allow exceptions even 
under the most sympathetic circumstances.
• This approach is inconsistent from a policy 
perspective. There are no restrictions on the 
genetic tests that can be performed on a fetus 
or on the reasons for which a woman may 
terminate a pregnancy.
• Prospective parents may go to “underground” 
providers, or, for those who can afford it, to 
another country where PGD is legal. 
• Banning PGD imposes a single moral or ethical 
perspective on those who may have different 
views.
• Any limit on decision making in human 
reproduction raises concerns about 
reproductive choice and could be subject to a 
Constitutional challenge.
• Bans on a medical procedure will be diffi cult 
to enact and enforce. 
• Bans at the state level can lead to 
inconsistencies in access to PGD.
Policy Options
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PRIVATE  Ethical Use
Option: Develop professional guidelines 
for ethical uses of reproductive genetic 
testing.  
A number of relevant medical professional 
societies have some reproductive genetic testing 
guidelines, including when a test should and 
should not be offered.  But the number of 
guidelines relative to the number of tests is small.  
As more tests become available, professional 
guidelines will become an important source 
of guidance for providers as to what testing 
is appropriate.  For example, guidelines may 
be needed on whether reproductive genetic 
testing of embryos and fetuses for sex selection, 
or predisposition to an adult-onset disease, is 
appropriate.  Guidelines will likely guide insurers’ 
reimbursement decisions for genetic tests.
Federal funding should be available to 
professional societies to support this work.
Federal funding would help professional groups 
devote adequate resources to this process, 
particularly as many more tests become 
available. 
The federal health agencies fund extensive 
research that underlies the development of new 
genetic tests and have a responsibility to aid in 
the translation of these fruits of research into 
quality health care.
Arguments for:
• Professional guidelines setting limits on 
reproductive genetic testing will provide 
guidance to providers and patients alike on the 
ethical use of these tests.
• Professional guidelines allow those with the 
most knowledge of testing to develop the 
framework for appropriate use.
• Professional guidelines are more easily 
developed and more easily revised in response 
to new scientifi c developments than legislation 
or regulation by agencies.
• By clearly delineating indications for testing, 
clear guidelines prevent over-testing by 
providers concerned about liability.
• Guidelines can be used by insurance companies 
to determine coverage, further limiting use. 
• Federal funding will help professional societies 
keep pace as many more tests become available.
Arguments against: 
• Guidelines are voluntary.  Providers are not 
compelled to comply.
• Providers may not have the appropriate 
expertise to establish guidelines based on 
morality or value judgments.
• Consensus on ethical uses is diffi cult. 
Guidelines may be in confl ict with the moral 
views of providers.
• Providers benefi t fi nancially from testing so 
there is inherent confl ict of interest when 
professional societies consider limit-setting.
• It is diffi cult for professional groups to devote 
adequate resources to this process, particularly 
as many more tests become available. 
• Guidelines may limit individual reproductive 
choices.
• Decisions about ethical uses should not be 
left entirely to the discretion of professional 
groups.  Broader societal consensus and input 
are needed.
PRIVATE  Ethical Use
Option: Limit uses of reproductive 
genetic testing through insurance 
coverage decisions.
Insurers could pay only for reproductive genetic 
testing done for reasons they deem acceptable 
and refuse to pay for reproductive genetic testing 
for reasons they determine to be unacceptable.  
Insurers would need to list and defi ne prohibited 
uses for enrollees.
Arguments for:
• Insurance companies’ coverage policies can 
operate as effective de facto enforcement, 
requiring prospective parents to follow 
guidelines for appropriate use in order to be 
reimbursed. 
• Insurers have mechanisms in place for 
determining when a test or procedure is 
“medically necessary.”
Arguments against: 
• It will be diffi cult for any entity, including 
insurers, to draw lines between acceptable and 
unacceptable reasons for testing.
• Enforcement of such policies will be diffi cult, 
requiring insurance companies to determine 
the reason testing is performed.  
• People able to pay out-of-pocket for 
reproductive genetic testing will be able to use 
it for any reason.
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Clinical Delivery of 
Reproductive Genetic Testing 
Services
Reproductive genetic tests can 
provide valuable information to 
patients, but many believe changes 
are needed to improve the quality 
and experience of genetic testing 
and related services. Th e quality 
of patient care would be enhanced 
if (1) health care providers were 
more knowledgeable about testing, 
(2) testing were off ered when 
prospective parents could make 
the best use of the information, 
and (3) prospective parents were 
provided all of the information and 
counseling needed to understand the 
choices that they are making about 
testing and the implications of those 
choices.
Most experts agree that genetic 
risk information and reproductive 
genetic testing options should be 
discussed with prospective parents 
before pregnancy. Th e health care 
provider should take a family history 
and assess genetic risk based on 
family history, maternal age and 
ethnic background and discuss 
carrier testing options. Carrier 
testing done before pregnancy 
provides prospective parents 
additional information about 
potential risks. 
Patient experiences with 
counseling about reproductive 
genetic testing vary greatly.  
Although some patients fi nd the 
counseling they receive adequate and 
appropriate, others report feeling 
not fully informed of the purpose of 
a test or what information the test 
will provide.  Prospective parents 
need to understand what testing is 
appropriate for their situation, the 
risks and benefi ts of the testing and 
the implication of having a child 
with the condition being tested 
for.  Th ey also need to have an 
opportunity to consider whether 
they want to pursue testing and what 
they might do with the information 
obtained from testing. 
Some observers have suggested 
that counseling include access to 
information from people living 
with genetic diseases and their 
families so that prospective parents 
may better understand the reality 
of having a child with the disease.  
Some believe that more widespread 
reproductive genetic testing means 
people with disabilities will be 
looked at as mistakes that could 
have been prevented through testing 
and society will reduce resources 
available for treatments, cures and 
support services.  
Prenatal genetic screening and 
testing can occur as early as the 
fi rst-trimester. Improving access to 
early prenatal care and encouraging 
women to pursue that care would 
increase the number of women who 
could consider earlier testing. 
Policy Options
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PRIVATE  Clinical Delivery
Option: Develop professional guidelines 
for appropriate delivery of reproductive 
genetic testing.  Federal funding should 
be made available to professional 
societies to support this work. 
Professional societies should develop 
comprehensive laboratory and clinical guidelines 
for the appropriate delivery of carrier testing, 
prenatal testing and PGD.  Guidelines should be 
reviewed and updated regularly. 
Guidelines should encourage providers to inform 
people about their risks and available testing 
including carrier testing before pregnancy, and 
encourage early prenatal care. Clear guidelines 
about appropriate indications for testing will not 
only help guide providers, it will help insurers 
make decisions about coverage. 
Federal funding should be made available to 
professional societies to support this work.
Federal funding would help professional 
groups devote adequate resources to this 
process, particularly as many more tests 
become available. The federal health agencies 
fund extensive research that underlies the 
development of new genetic tests and have a 
responsibility to aid in the translation of these 
fruits of research into quality health care.
Arguments for:
• Professional guidelines that ensure the right 
patients are offered the right test at the right 
time with the right information will improve 
the quality of care that is delivered. 
• Guidelines will help ensure that tests are 
offered appropriately and interpreted 
accurately.
• Professional guidelines can be revised in 
response to new scientifi c developments.
• Professional societies usually have regular 
communication with providers, optimizing 
chances for education and implementation 
among providers.
• Federal funding will help professional societies 
keep pace as many more tests become available.
• Clear guidelines will help prevent over-testing 
by providers who are concerned about liability 
and under-testing by providers who do not 
know about, or do not personally approve of, 
testing.
Arguments against: 
• Guidelines are diffi cult, expensive and time-
consuming to develop.
• Providers may disagree about appropriate 
testing guidelines, frustrating consensus.
• Given the many types of providers who may 
deliver this care, (obstetrician-gynecologists, 
family practice physicians, internists, nurse-
midwives, nurse practitioners, geneticists and 
genetic counselors), individual professional 
societies may not be broadly-based enough to 
reach all those concerned.
• Providers benefi t fi nancially from testing so 
there is inherent confl ict of interest when 
professional societies consider limit-setting.
• Guidelines alone will not result in a change in 
provider behavior.  Providers must also accept 
the guidelines, be educated and trained in 
their use and use them consistently.
• Guidelines are voluntary.  Providers are not 
compelled to comply.
• Guidelines may have the effect of limiting 
individuals’ choices.
• Guidelines that recommend offering 
reproductive genetic testing for specifi c 
diseases may be perceived as making a value 
judgment about whether and what diseases 
should be avoided.
• Guidelines that recommend offering tests and 
counseling about reproductive genetic testing 
may be in confl ict with the moral views of 
providers.
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PRIVATE  Clinical Delivery
Option: Improve healthcare provider 
education about reproductive genetic 
testing.
Providers, including obstetrician-gynecologists, 
family practice physicians, internists, nurse-
midwives and nurse practitioners should be 
knowledgeable about reproductive genetic testing 
in order to counsel patients about the risks, 
benefi ts and implications of testing, and refer for 
genetic counseling when appropriate.  This would 
ensure voluntary reproductive genetic testing with 
appropriate consent.
Arguments for:
• This approach will result in health care 
providers being better prepared to obtain 
a family history, assess risk and discuss 
reproductive genetic testing and reproductive 
options with patients before pregnancy. 
• Better informed providers will lead to better-
informed patients.
• An increase in genetic “literacy” among 
providers will lead to appropriate referrals to 
genetic counseling when necessary.  
Arguments against: 
• There are limited resources for genetic 
literacy training and maintaining up-to-date 
educational materials and guidelines.
• Given growing economic pressures, health care 
providers may simply not have adequate time 
to assess genetic risks and discuss reproductive 
genetic testing including carrier testing with 
their patients. 
• Guidelines offering tests and counseling about 
reproductive genetic testing may be in confl ict 
with the moral views of providers.
PRIVATE  Clinical Delivery
Option: Educate patients, especially 
those of reproductive age, about 
reproductive genetic testing.  
Professional societies, consumer and patient 
groups, government agencies and/or schools and 
universities could undertake a public education 
campaign to emphasize the benefi t of pre-
conception care that includes a family history, 
risk assessment, genetic counseling and offering 
carrier testing.  In addition, every individual 
should know about the benefi ts of receiving 
the earliest possible prenatal care, which allows 
patients the most choices about early prenatal 
genetic screening and testing.
Arguments for:
• Giving information directly to consumers will 
increase number of people knowledgeable 
about reproductive genetic testing and allow 
them to make more educated choices.
• Better-informed consumers will create a 
demand for providers to provide quality 
counseling and care. 
• This option is in keeping with trends towards 
patient self-education and autonomy in health 
care decision making.
Arguments against: 
• Patient demand for counseling and testing 
may be so high as to strain the ability of 
providers to meet demand.
• Patient education alone is not enough.  
Providers must also be prepared to discuss, 
order and interpret genetic tests.
• Creating patient demand for carrier and early 
prenatal testing may lead to inappropriate 
testing and over-testing.
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PRIVATE  Clinical Delivery
Option: Increase genetic counseling 
services and information before and 
during pregnancy. 
Reproductive genetic tests provide information 
that is the basis for profound decisions.  Yet 
patients often receive little guidance when 
deciding whether or not to pursue testing and are 
overwhelmed trying to make decisions based on 
test results once they are received. 
Patients should have access to providers, including 
genetic counselors, who are trained to help people 
understand the tests and confront the decisions 
that could come from test results.  Patients should 
also have information about the condition the test 
is for and what it means for affected individuals 
and their families medically, emotionally and 
fi nancially.  Improved insurance coverage of 
counseling services would also allow providers to 
ensure that patients understand the decisions they 
are making.  
Some disability advocates believe that demand 
for prenatal testing and PGD would be reduced 
if prospective parents had more balanced 
information about the condition for which testing 
is being sought and the reality of caring for a child 
with the condition.  Some have suggested that 
prospective parents should have the opportunity 
to meet with those living with the particular 
condition and their families. Patient advocacy 
organizations working on behalf of people with 
the condition could work with providers to 
facilitate such interactions.
Arguments for:
• Access to quality counseling will mean patients 
are better able to make fully informed 
decisions about carrier tests as well as prenatal 
screening and diagnostic tests.
• As more choices in genetic testing become 
available, more counseling is necessary to 
help patients understand the scope of choices 
before them and manage the anxiety that may 
come from “too much information.”
• Non-directive counseling by trained genetic 
counselors  may alleviate the concerns that 
some patients have raised about feeling 
pressured either to agree to testing or to refuse 
it.
• Covering genetic counseling services will 
increase access to counseling from providers 
with the necessary training and expertise.
• More information about the condition being 
tested for could reassure parents, reducing the 
number of prospective parents seeking prenatal 
genetic testing, abortions and PGD. 
Arguments against: 
• Additional funding and other resources would 
be necessary to adequately train providers 
to do genetic counseling or to increase the 
number of certifi ed genetic counselors.
• As more tests become available to more people 
for many more diseases, it may be impossible 
to adequately counsel every patient about 
every test being offered.
• If done incorrectly, counseling may be 
perceived as pressure to agree to testing.
• “Non-directive” genetic counseling may be 
problematic because it does not prevent 
patients from making decisions that may be 
viewed as unethical by some.
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GOVERNMENTAL   Accuracy & Safety
Option: Increase federal oversight of 
genetic testing. 
FDA, CMS (through CLIA) and/or CDC should ensure 
that tests are approved before becoming available, 
laboratories performing reproductive genetic 
testing are certifi ed and competent to perform 
the tests at issue, procedures related to testing are 
competently performed and data are collected 
to assess how well these tests and procedures are 
performed. 
These agencies have played a limited role in the 
past. They may have the authority currently to 
expand their role. In addition, Congress could pass 
legislation delegating to these federal agencies the 
authority to:
• License and inspect facilities involved with 
genetic testing including laboratories and clinics 
providing PGD and IVF.
• Establish analytic and clinical validity and 
possibly clinical utility before tests get to market.
• Regulate and monitor how test results are 
reported to providers and patients.
• Collect data on test performance, accuracy 
and reliability of testing, safety of prenatal 
procedures (amniocentesis, CVS), and health 
outcomes of children born following PGD. 
• Ensure patients are giving informed consent.
These agencies could also take on the role of 
overseeing the ethical use of reproductive genetic 
testing.
Arguments for:
• Federal agencies have expertise in oversight 
and could signifi cantly improve the accuracy 
and safety of reproductive genetic testing.
• This approach gives clear authority for the 
federal government to take the lead.
• Federal oversight will create greater confi dence 
in genetic testing.
• The legislative process to extend federal 
oversight will stimulate a productive public 
discussion about how to effectively oversee 
genetic testing.
• This approach will allow monitoring of the 
impact of genetic testing on individuals, 
families and society.
• The data collected by the government will 
inform future policymaking.
Arguments against: 
• It may be diffi cult to create the political will or 
consensus to increase oversight of the accuracy 
and safety of genetic testing.
• It is diffi cult to create stable, effective and 
non-partisan oversight. For example, if testing 
cannot occur without licensing or approval 
by a single government authority, lawmakers 
who disagree with an agency’s decisions could 
effectively halt agency actions by denying the 
agency funding.
• Increased oversight will affect access.  In 
general, more scrutiny will mean restricted or 
delayed availability and increased costs. 
• Authorizing a federal agency to determine 
clinical utility will be controversial, as the 
determination of whether a test provides 
useful information depends on an individual’s 
situation, perspective and values.  These 
decisions should be left to providers and 
patients.
• Federal oversight will give explicit government 
approval to practices that many people reject.
Accuracy and Safety of 
Reproductive Genetic Testing
Th e accuracy and safety of 
reproductive genetic testing is of the 
utmost importance.  Th e information 
tests provide is the basis for profound 
decisions about when, whether and 
how to bear children.  
As is the case with most medical 
tests and procedures, no reproductive 
genetic test or procedure can be 
100 percent accurate.  Th ere will 
always be some false positive and 
false negative results, whether due 
to inherent problems with the test, 
errors in the performance of the test 
or problems in interpretation.  False 
positive results can lead to signifi cant 
anxiety for the patient, the need for 
more testing and potentially the 
termination of healthy pregnancies. 
False negative results can result in the 
unexpected birth of aff ected children.
Government oversight in this area 
is limited and fragmented.   Th ere is 
no government review of the analytic 
or clinical validity, or clinical utility, 
of a genetic test before it is marketed.  
FDA has a small role, as does CMS 
through CLIA.  Without any central 
and comprehensive oversight, many 
if not most aspects of genetic testing 
occur without any government 
monitoring. 
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GOVERNMENTAL    Accuracy & Safety
Option: Increase role of state 
governments 
The activities, authority and responsibilities of 
state entities such as public health agencies vary 
from state to state.  In general, all endeavor to 
infl uence public health policy and practice. They 
promote health by tracking and monitoring 
disease, promoting disease prevention, 
screening newborns, regulating laboratories, 
licensing health care providers and delivering 
basic health services. 
It is diffi cult to create a uniform policy approach 
for state public health agencies because, 
statutorily and bureaucratically, they take so 
many different forms. Nonetheless, each state 
could take its basic charge to protect the public 
health and apply it to improving the safety and 
accuracy of reproductive genetic testing.
Some states already have programs in place 
that oversee reproductive genetic testing.  For 
example:
• Washington and New York states certify 
laboratories performing testing and the 
oversight is extensive enough that laboratories 
passing the state requirements are deemed 
CLIA compliant. 
• In New York state, the oversight of the tests 
is analyte and test specifi c, making for more 
robust oversight.
• California oversees the state maternal serum 
screening program.  Women who are at high 
risk based on the screening test results are 
offered follow-up services including genetic 
counseling, ultrasound and amniocentesis. 
Participation in the screening, testing and 
follow-up services is voluntary.  State approval 
is needed for a laboratory or diagnostic center 
to participate in this program. Nearly every 
laboratory or center in the state meets the 
state standards. and the overall quality of care 
in the state has improved as a result. 
Arguments for:
• State initiatives may be more politically 
feasible when a national approach proves 
too diffi cult.
• A state-by-state approach allows additional 
fl exibility depending on the needs and 
resources of the state.
• State approaches are often testing grounds 
for systems that may later be adopted 
nationally.
Arguments against: 
• A state-by-state approach means that safety 
and accuracy may vary depending solely on 
where the patient lives. 
• State public health agencies already are 
stretched thin and would be hard pressed to 
fi nd additional resources and develop new 
expertise to address new fi elds.
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PRIVATE  Accuracy & Safety
Option: Develop professional guidelines 
to improve accuracy and safety of 
reproductive genetic testing. 
Professional societies could develop guidelines for 
laboratories and health care providers addressing 
the performance of reproductive genetic testing 
and the delivery of test results. Guidance could 
include information about how, when and for 
whom to order specifi c tests and how to interpret 
results.  Guidelines for laboratory directors 
and technicians could address best laboratory 
practices.
Federal funding should support guideline 
development in order to help professional 
societies keep pace as many more tests become 
available.
Arguments for:
• Guidelines help ensure that patients are 
appropriately informed, tests are administered 
and interpreted accurately and the test results 
are useful.
• Professional guidelines are more easily 
developed and more easily revised in response 
to new scientifi c developments than legislation 
or regulation by agencies.
• Federal funding will provide the resources 
necessary for this process, particularly as many 
more tests become available. 
• Clear guidelines provide the guidance needed 
to prevent over-testing by providers concerned 
about liability.
Arguments against: 
• Providers may disagree about testing 
guidelines, frustrating consensus.
• Providers benefi t fi nancially from testing so 
there is inherent confl ict of interest when 
professional societies consider limit-setting.
• Guidelines alone will not result in a change 
in behavior.  Laboratories and providers must 
also accept the guidelines, be educated and 
trained in their use and use them consistently.
• Guidelines are voluntary.  Providers and 
laboratories are not compelled to comply. 
• It is diffi cult for professional groups to devote 
adequate resources to this process, particularly 
as many more tests become available. 
• Guidelines that recommend offering tests and 
counseling may be in confl ict with moral views 
of providers.  
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PRIVATE  Accuracy & Safety
Option: Establish professional 
certifi cation programs for profi ciency in 
reproductive genetic testing.
In addition to creating voluntary guidelines 
for reproductive genetic testing, professional 
organizations could establish certifi cation programs 
for providers and others involved in reproductive 
genetic testing (physicians, geneticists, counselors, 
embryologists, technicians) similar to the specialty 
boards that currently certify physicians in different 
practice areas.
Although such certifi cation may be voluntary, once 
established it often becomes self-enforcing: in 
many cases insurers will not reimburse for services 
provided by non-certifi ed providers or laboratories. 
and patients know to look for certifi ed care.  In 
addition, state licensing boards may use such 
certifi cation in their own licensing or approval 
determinations.
 
There are a number of entities whose expertise could 
contribute to a professional certifi cation system for 
reproductive genetic testing.  The American Board 
of Medical Genetics (ABMG), the American Board of 
Obstetrics and Gynecology (ABOG), and the American 
Board of Genetic Counselors (ABGC) are among 
those whose certifi cation encompasses specialists 
most likely to be involved with reproductive genetic 
testing. Other medical and nursing boards could also 
contribute.  
Other programs certify laboratory personnel.  The 
American Association of Bioanalysts (AAB) maintains 
a Board of Registry, the primary purpose of which is 
to identify laboratory specialists who meet minimum 
standards. The American College of Medical Genetics 
(ACMG) in conjunction with the College of American 
Pathologists (CAP) runs voluntary programs certifying 
laboratories in a range of areas, and has developed 
some standards and guidelines for clinical genetics 
laboratories working in reproductive genetics, 
although no guidelines bear specifi cally on PGD.
Individual organizations could develop their own 
certifi cation programs or several could collaborate in 
a comprehensive certifi cation system that draws on 
several areas of expertise.
Arguments for:
• Certifi cation of personnel will improve the 
quality of services by establishing training 
criteria and requiring a demonstration of 
competency. 
• Certifi cation developed jointly by relevant 
organizations will have the benefi t of 
combining multiple areas of expertise to set 
high standards for clinical and laboratory 
services.
• Certifi cation developed and implemented 
through professional organizations will be 
especially responsive to developments in 
science and technology.
Arguments against: 
• Because there are many kinds of providers and 
laboratory personnel involved in reproductive 
genetic testing, developing a comprehensive 
certifi cation system that draws on the expertise 
of several professional organizations will be 
challenging.
• Certifi cation requirements have often 
functioned to limit competition, suppress 
innovation and increase costs.
• Private sector certifi cation will be used as 
an argument to delay or eliminate federal 
oversight.
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Access to Reproductive Genetic 
Testing
For many people, the cost 
of reproductive genetic testing 
and the uncertainty of insurance 
coverage means they are not off ered 
reproductive genetic testing or 
do not receive testing services at 
the appropriate time.  In addition, 
some people refuse reproductive 
genetic testing because they fear the 
consequences of insurers having 
information about their child’s 
genetic makeup before birth.  
It is diffi  cult to determine, 
based on available information, 
whether and to what extent insurers 
cover genetic counseling, carrier 
testing, prenatal screening and 
testing and PGD.  In general, most 
insurers cover testing they consider 
“medically necessary,” a concept that 
some plans defi ne clearly and others 
do not.  Th ere is a strong element of 
subjectivity to the determination of 
medical necessity. Insurers generally 
prefer to wait for strong evidence of 
clinical validity, utility and cost-
eff ectiveness.  
A complicated regulatory 
scheme limits the impact of state 
and federal insurance laws on 
insurance coverage of specifi c 
services. Governmental mandates 
are typically needed to reach all 
insured individuals.  But, under 
federal law (ERISA), employee 
health benefi t packages in which 
the employer bears some or all of 
the risks of paying for the costs of 
care are exempt from state insurance 
mandates. Th us, even if a state law 
required coverage of reproductive 
genetic testing, people in employer-
sponsored plans would not be 
guaranteed this particular benefi t. 
Approximately 61 million Americans 
are in employer-sponsored plans that 
are exempt from state mandates.  
Th ere could be pressure on 
insurers not to pay for some forms 
of reproductive genetic testing given 
the moral issues involved. And 
from a health policy standpoint, 
there could be an argument made 
that there are many other health 
care needs that should be covered 
fi rst before the newest reproductive 
genetic test. 
Medicaid 
Medicaid pays for medical 
assistance for individuals and 
families with low incomes.  It 
is jointly funded by the federal 
government and state governments.  
Federal law determines the 
minimum standards that state 
Medicaid programs must meet to 
receive federal funds.  Beyond that, 
each state determines the benefi ts 
included in its program.    
Because Medicaid benefi ts 
vary by state (within certain 
federal guidelines), it is diffi  cult 
to know how many states cover 
reproductive genetic services.  In the 
1990s, several surveys found that 
amniocentesis was widely covered.  
Medicaid eligibility rules may 
present a barrier to coverage of 
reproductive genetic testing.  While 
the program is designed to provide 
services to low-income pregnant 
women, children and families, in 
many cases, a woman is not eligible 
for Medicaid until she is pregnant.  
Th us, Medicaid coverage may not be 
available for her to obtain counseling 
or carrier testing pre-pregnancy.  
Eligibility rules may also aff ect access 
to prenatal testing.  Because most 
women are not eligible for Medicaid 
before pregnancy, if a woman does 
not know she is pregnant, or does 
not apply for Medicaid until she is 
well into her pregnancy, she will miss 
the opportunity to have some of the 
earlier prenatal tests.
Medicaid Managed Care, which 
enrolls Medicaid recipients in 
managed care plans, also plays a 
role in how care is delivered to the 
Medicaid population.  While it is 
diffi  cult to know for sure, Medicaid 
Managed Care probably provides 
greater coverage for carrier testing 
and prenatal testing when they are 
covered in the general Managed Care 
plan (Medicaid and non-Medicaid).  
A survey of state Medicaid directors 
would be needed to know the extent 
of Medicaid and Medicaid Managed 
Care coverage of reproductive 
genetic testing.  
Medicaid’s policy towards 
abortion is restrictive.  Federal 
Medicaid funds may not be used 
to pay for abortions except those 
necessary to save the life of the 
mother or in cases of rape and incest. 
Some states provide state funds 
to pay for abortions for Medicaid 
recipients.
 
A related federal program is 
State Children’s Health Insurance 
Program (SCHIP). Th is program 
allows states to off er health insurance 
for children, up to age 19, who are 
not already insured. SCHIP is a state 
administered program and each state 
sets its own guidelines regarding 
eligibility and services within certain 
federal restrictions.
Medicare is commonly known 
as the national health insurance 
program for people over 65 years 
of age, but it also provides coverage 
for some people under 65 with 
disabilities.  SCHIP and Medicare 
each reach some women who are 
of reproductive age or already 
pregnant.
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GOVERNMENTAL  Access
Option: Enact federal and/or 
state laws to prohibit genetic 
discrimination.
Legislation to prevent the misuse of genetic 
information by employers and insurers would 
reassure parents who turn down testing, because 
they fear that the information from testing will 
be used against their child in the future.
Arguments for:
• Laws against genetic discrimination will ease 
prospective parents’ fears that reproductive 
genetic test results will be used against them 
or their child in insurance or employment 
decisions.
• Such laws will eliminate one barrier to 
accessing reproductive genetic testing.
Arguments against: 
• There is little documented evidence that 
insurers or employers are using genetic 
information in a discriminatory manner.
• Legislation in this area will create burdens for 
insurers and employers and increase costs.
• Genetic information should not be treated 
differently from other medical information. 
• Creating legislative protections specifi cally for 
genetic information will increase the stigma 
associated with genetic testing.
GOVERNMENTAL  Access
Option: Require private insurance 
coverage of reproductive 
genetic testing consistent with 
recommendations by qualified 
professional groups. 
Federal and/or state legislation could mandate  
coverage of reproductive genetic testing by 
private insurers. There is precedent for such an 
approach in federal and state laws requiring 
coverage of particular benefi ts.  By following 
professional societies’ guidelines on genetic 
counseling, carrier testing, prenatal screening 
and testing and PGD, insurers will make 
coverage decisions consistent with quality health 
care.
Arguments for:
• Increasing access to reproductive genetic 
testing makes good public health sense, 
giving people information about their risk of 
having a child with a genetic disease.
• Insurance companies typically weigh 
professional guidelines heavily in 
determining coverage of testing. This option 
would create additional stimulus to adopt 
coverage policies consistent with guidelines.
Arguments against: 
• Expanded coverage could raise premiums for 
everyone as a result.
• There are a lack of suffi cient data on cost-
effectiveness of testing to conclude that 
insurance companies should cover such 
testing.
• This approach may create new problems.  
Insurance companies could use the results 
of testing individuals to discriminate, raising 
premiums or denying coverage to individuals 
based on their genes, unless laws are 
enacted to prevent access to and use of this 
information. 
• Professional guidelines are often slow in 
development and address only a small 
subset of the tests available.  In practice, 
this approach may mean that insurance 
companies will cover only a few tests, reducing 
access to those tests less commonly used or 
recommended.
• People object to some testing, particularly 
prenatal testing and diagnosis and PGD, on a 
range of ethical grounds.  Mandating coverage 
treats them as universally accepted.
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GOVERNMENTAL Access
Option: Require public programs to 
cover reproductive genetic testing 
consistent with recommendations of 
qualifi ed professional groups. 
Congress could require Medicaid (as well as SCHIP 
and Medicare, where applicable) to cover testing 
recommended by professional groups’ guidelines. 
Medicaid is discussed in more detail below.  There 
is precedent for such an approach in federal laws 
requiring public payors’ coverage of particular 
benefi ts.  By following professional societies’ 
guidelines on genetic counseling, carrier testing, 
prenatal screening and testing, and PGD, these 
programs will provide quality care to enrollees. 
In addition, the federal government, the nation’s 
largest employer, has signifi cant direct regulatory 
control over the Federal Employee Health Benefi t 
Plan (FEHBP). FEHBP provides health insurance 
to more than eight million federal enrollees and 
their dependents, including approximately 1.2 
million women of childbearing age. Congress 
could require FEHBP plans to cover testing 
recommended by professional groups’ guidelines.  
Public programs often drive private insurance 
generally, and could lead to reforms throughout 
the private insurance market.
Arguments for:
• Increasing access to reproductive genetic 
testing makes good public health sense, giving 
people information about their risk of having a 
child with a genetic disease.
• Insurance companies and other payors 
typically weigh professional guidelines heavily 
in determining coverage of testing. This 
option would formalize that process for public 
programs.
• This approach provides a strong incentive for 
insurers and providers to work together to 
improve the proper use of reproductive genetic 
testing.
Arguments against: 
• People object to some testing, particularly 
prenatal screening and testing and PGD, on a 
range of ethical grounds.  Mandating coverage 
and using federal funds to pay for tests treats 
them as universally accepted.
• Such a mandate may raise the cost of public 
programs to taxpayers.  There are a lack of 
suffi cient data on cost-effectiveness of testing 
to know the fi nancial impact of mandating test 
coverage.
• Professional guidelines are often slow in 
development and address only a small 
sample of the tests available.  In practice, this 
approach may mean that federal programs 
will cover only a few tests, reducing access to 
those tests that are less commonly used or 
recommended.
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GOVERNMENTAL Access
Option: Expand Medicaid eligibility and 
outreach to give low-income women 
better access to reproductive genetic 
testing.
Many women are not eligible for Medicaid 
until after they become pregnant.  As a result, 
many low-income women do not have access to 
pre-conception genetic counseling and carrier 
screening to inform reproductive decision making. 
In addition, many may not receive early prenatal 
care including genetic counseling and prenatal 
screening and testing because they do not know 
that they are eligible for Medicaid until after the 
pregnancy is well underway.   
Expanding Medicaid to allow access to pre-
conception counseling and carrier testing and 
better patient education about reproductive 
genetic testing would give low-income women 
better information about their level of risk, 
their pregnancies and their testing options.  
With additional resources, federal and state 
governments could also make PGD available to 
Medicaid recipients.
Arguments for:
• Allowing low-income women the opportunity 
to make fully informed reproductive decisions 
with better access to reproductive genetic 
testing makes good public health sense, giving 
people information about their risk of having a 
child with a genetic disease.
• Genetic counseling and carrier testing before 
pregnancy allows better prenatal care by 
alerting providers and patients to the possibility 
of a high-risk pregnancy that may be better 
monitored and followed.  
• PGD services provide an important benefi t for 
Medicaid  recipients by increasing their chance 
of having healthy children free of genetic 
disease.
Arguments against: 
• Expanding Medicaid eligibility will increase 
costs, requiring additional state and/or federal 
funding.
• People object to prenatal screening and testing 
on a range of ethical grounds.  Mandating 
coverage and using federal funds to pay for 
tests treats them as universally accepted.
• Such changes may raise the costs of public 
programs to taxpayers.  There are a lack of 
suffi cient data on cost-effectiveness of testing 
to know the fi nancial impact of covering these  
tests.
• Medicaid reform should focus on providing 
basic preventive care, diagnosis and treatment 
to patients, not on providing every possible 
technology, especially when it is relatively 
untested and very expensive.
• Few Medicaid patients will pursue PGD. 
Creating a mandate is thus a solution without 
a problem.
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PRIVATE Access
Option: Use employer purchasing 
power.
Employers could ensure access to reproductive 
genetic testing by making sure those benefi ts are 
included in their employee benefi t plans.
Large employers spend signifi cant money on 
purchasing health care for their employees. 
Smaller employers often work through purchasing 
coalitions, which are groups of employers who use 
their collective leverage in purchasing health care 
for their employees. Together, these employers 
determine the health benefi ts that will be made 
available to the millions of Americans who 
depend upon their employer for health insurance, 
and infl uence the benefi ts insurers offer more 
generally.
Employers make purchasing decisions based 
primarily on an analysis of what benefi ts they 
think will result in a more productive workforce 
(e.g., fewer sick days, greater effi ciency at work). If 
reproductive genetic testing is shown to increase 
productivity, the end result would be cost savings 
to employers.
Arguments for:
• This non-governmental solution avoids the 
challenge of passing new laws for insurance 
mandates.
• This approach allows employers to determine 
what is best for a specifi c workforce population.
Arguments against: 
• Most employers do not have enough 
purchasing power to make tailored purchasing 
decisions. They make decisions based on what 
the market offers them, which may or may not 
conform to their notion of what benefi ts are 
best for their employees. 
• It is diffi cult to quantify the costs and benefi ts 
of reproductive genetic testing in the short 
term, which is the time frame that employers 
must consider given the short time most 
people stay in a job.
PRIVATE Access
Option: Coordinate and improve 
insurers’ research into coverage 
decisions.
Insurers and other payors typically rely on a 
range of information including technology 
assessments and cost-benefi t analyses to make 
decisions about coverage of new technologies 
such as reproductive genetic testing.
Insurers could coordinate this research by 
creating a task force or other independent entity 
to look at these issues.  This approach could 
create more consistency and predictability in 
coverage of genetic counseling, carrier testing, 
prenatal genetic screening and diagnosis and 
PGD.
Arguments for:
• Coordination among payors will allow 
companies to share information about cost-
effectiveness and health impacts of various 
coverage decisions.
• More consistent policies create predictability 
and less anxiety for patients wondering if 
their insurance will cover a particular test or 
procedure.
Arguments against: 
•Most payors are for-profi t entities competing 
with each other.  They will be reluctant to 
collaborate with their competitors in such 
research.
• Often coverage policies are made in response 
to individual cases, making industry-wide 
consistency diffi cult.
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PRIVATE Access 
Option: Provide financial 
assistance for PGD through IVF 
clinics.
IVF clinics and PGD providers and laboratories 
could offer fi nancial assistance directly to 
prospective parents seeking PGD.
Due to the high cost associated with assisted 
reproductive technologies, some IVF programs 
offer IVF on a “shared-risk,” “warranty,” “refund” 
or “outcome” basis. Shared-risk plans operate 
by refunding a portion of the fee paid for one 
or more IVF cycles in the event that they do not 
result in a pregnancy or live birth of a child. 
Typically, shared-risk patients pay a higher fee 
than other IVF patients and, in return, receive 
a refund of 70 to 100 percent of this fee if 
treatment fails. Accordingly, someone who 
succeeds in having a baby may pay more under 
the shared-risk plan than she would have under 
a traditional fee-for-service plan. However, this 
option helps ensure that unsuccessful couples 
will have the fi nancial resources to pursue other 
options for starting a family.
In addition, many fertility clinics offer IVF at a 
reduced price to patients who provide their eggs 
to other patients, although some critics say this 
practice is coercive and creates psychological 
issues for some patients.
Clinics or laboratories could also offer discounts 
or payment plans for families who could not 
otherwise afford PGD. For example, a clinic could 
offer discounted IVF services if PGD is included.
Arguments for:
• Discounts and shared costs will give 
people access to PGD and IVF services that 
otherwise would be out of reach.
Arguments against: 
• Because the market for PGD is signifi cantly 
smaller than the IVF market, and will continue 
to be for some time, clinics may not want to 
offer discounts on PGD services.   
• Critics fi nd some fi nancial assistance programs 
coercive because they create strong incentives 
for patients to donate eggs or embryos.
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While it is sometimes fashionable 
in science and policy to opine that 
“more research is needed,” in the 
case of reproductive genetic testing, 
critical data are truly needed to 
develop eff ective, appropriately 
tailored and evidence-based policy. 
One key question for each 
technology we have discussed is 
how many people are currently 
using it or are likely to adopt it in 
the future.  Defi ning the size of the 
likely population of users is critical 
because it informs the type of policy 
approach to apply. 
Another important data question 
is how these technologies are being 
delivered to patients and what 
barriers to access are encountered 
by those for whom they might be 
benefi cial.  Th ese questions include 
(1) how many people are being 
off ered testing, how many accept 
or reject it and the reasons for 
their decisions, (2) whether carrier 
testing is off ered preconception or 
post-conception and what factors 
infl uence the timing of testing, (3) 
whether pregnant patients receive 
information about options for 
prenatal screening and testing early 
enough in the pregnancy to make 
fully informed choices, (4) whether 
and under what circumstances 
these technologies are covered by 
insurance and how that infl uences 
access, and (5) for what purposes 
these technologies are being off ered 
and used.
Also of great importance is 
obtaining more information about 
the safety and accuracy of these 
technologies. Th is information is 
particularly diffi  cult to obtain, since 
these technologies are regulated 
in a piecemeal and decentralized 
way. Tests and procedures are 
typically delivered as part of the 
practice of medicine, rather than in 
a research context.  Nevertheless, 
eff ective policymaking requires 
accurate information concerning 
the outcomes of using these 
technologies.  For example, how 
oft en do genetic tests lead to false 
negative or false positive results? 
How oft en are results of these tests 
misreported, and what is the result 
of such inaccurate information being 
transmitted? What is the benefi t of 
using certain tests and is such benefi t 
adequately considered before they 
are introduced clinically? 
PGD, the newest technology, 
raises some specifi c questions.  Th ere 
are incomplete and confl icting data 
on the long-term health eff ects of 
IVF for women and children and 
no systematic studies on the health 
and developmental outcomes for 
children born following PGD. Does 
the embryo biopsy process damage 
embryos in a way that decreases 
their viability or injures the resulting 
child? How oft en does PGD fail to 
detect a genetic mutation? Does 
aneuploidy screening improve IVF 
results?  
Many questions have been raised 
about the potential societal impact 
of reproductive genetic testing, 
but little information exists in this 
area. In particular, what impact 
does increased testing have on 
family relationships, particularly 
between parents and children? In 
addition, disability advocates have 
raised questions about whether, in 
a society where genetic diseases 
can be avoided, resources will be 
provided to those already living 
with disabilities, including both 
support services and funding for 
research to develop treatments.  
Some also question whether society’s 
perception of people with disabilities 
will become more negative. 
Many questions exist about the 
extent to which insurance companies 
cover reproductive genetic testing.    
It would also be useful to know 
how state Medicaid directors have 
handled new reproductive genetic 
technologies and how Medicaid 
Managed Care may have aff ected 
access by Medicaid recipients.
 
Any proposal for research begs 
the question of who will do it and 
who will fund it. In order to collect 
such a vast array of data, a number of 
diff erent reporting mechanisms may 
need to be established.  
As we have described in earlier 
chapters, some reporting systems, 
such as the FCSRA-mandated IVF 
reporting requirements and the 
PRAMS program, are already in 
place.  Current IVF reporting to the 
CDC mandated by FCSRA does not 
include data on whether PGD was 
used, but this information could 
be added.  PRAMS collects state-
specifi c, population-based data on 
maternal attitudes and experiences 
prior to, during and immediately 
following pregnancy.  Currently, 
almost no information gathered 
relates to carrier testing, prenatal 
screening or prenatal testing.  Th ese 
questions could easily be added to 
the questionnaire. 
Establishing a patient registry 
would allow data collection on 
the long-term health of children 
born aft er PGD.  ESHRE, a PGD 
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professional society based in Europe, 
has established such a registry.  In 
the U.S., longitudinal studies of 
women who have undergone IVF 
and children born following IVF 
and PGD would provide valuable 
information about the safety and 
risks of IVF and embryo biopsy.   
Although it is challenging to study 
the societal impact of reproductive 
genetic testing, research could track 
changes in resources available for the 
disabled and in societal perceptions 
over time. In addition, a survey of 
private and public insurers would 
provide additional insight into the 
access questions raised in this report.
For laboratory and clinical 
research that involves embryos, 
funding from the federal 
government is restricted by the 1996 
Congressional ban that prohibits 
federal funding of research in 
which human embryos are created, 
or subjected to greater risk than 
that permitted for a fetus in utero. 
However, notwithstanding the 
ban, research to answer many 
questions concerning reproductive 
genetic testing would not involve 
the creation, destruction or harm 
of embryos and thus would not 
be subject to the federal ban. In 
addition, the federal ban in no 
way restricts the private sector, 
including both industry and non-
profi t foundations and advocacy 
groups, from funding research 
involving human embryos that 
could help assess and improve 
techniques. Research sponsors, 
either individually or collaboratively, 
could establish a common set of 
research priorities, ethical standards 
for research and data collection and 
distribution requirements. 
Finally, we note that constructing 
policy that is responsive to and 
refl ective of the public’s mores 
and preferences requires a more 
detailed understanding of informed 
public attitudes toward this new 
technology. One option is to use 
public or private resources to 
increase societal discussion about 
reproductive genetic testing.  In 
particular, increasing the input 
of key stakeholders, including 
patients who have chosen to use or 
reject reproductive genetic testing, 
providers and advocates, could 
provide valuable perspective to any 
entity or individual considering 
limits on reproductive genetic 
testing. 
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ACMG
American College of Medical Genetics
ACOG




analyte specifi c reagent
ASRM
American Society for Reproductive Medicine
CAP
College of American Pathologists
CDC




Clinical Laboratory Improvement Amendments 
CLIAC
Clinical Laboratory Improvement Advisory 
Committee
CMS








Employee Retirement Income Security Act
ESHRE
European Society for Human Reproduction and 
Embryology
FCSRA
Fertility Clinic Success Rate and Certifi cation Act 
FDA
Food and Drug Administration
FD&C Act
Federal Food, Drug and Cosmetic Act
FEHBP
Federal Employee Health Benefi t Plan
HHS






in vitro diagnostic device
IVF
in vitro fertilization 
NIH
National Institutes of Health 
PCB






Prenatal Genetic Diagnosis International Society 
PRAMS




Secretary’s Advisory Committee on Genetics, Health, 
and Society
SACGT
Secretary’s Advisory Committee on Genetic Testing
SART
Society for Assisted Reproductive Technologies
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